




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 207/34, 401/12, 233/90 A61K 31/40, 31/415</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/13838</p> <p>(43) International Publication Date: 20 August 1992 (20.08.92)</p>
<p>(21) International Application Number: PCT/CA92/00051</p> <p>(22) International Filing Date: 5 February 1992 (05.02.92)</p> <p>(30) Priority data: 650,616 6 February 1991 (06.02.91) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 650,616 (CIP) Filed on 6 February 1991 (06.02.91)</p> <p>(71) Applicant (for all designated States except US): SYNPHAR LABORATORIES, INC. [CA/CA]; #24, Taiho Alberta Center, 4290-91A Street, Edmonton, Alberta T6E 5VE (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : LOWN, J., William [CA/CA]; 4704-117A Street, Edmonton, Alberta T6H 35L (CA). MICETICH, Ronald, George [CA/CA]; 12 Braeside Terrace, Sherwood Park, Alberta T6E 5V2 (CA).</p>		<p>(74) Agent: RICHERS, McKENZIE & HERBERT; Suite 2900, 2 Bloor Street East, Toronto, Ontario M4W 3J5 (CA).</p> <p>(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.</p> <p>Published <i>With international search report.</i></p>

BEST AVAILABLE COPY

(54) Title: OLIGOPEPTIDE ANTIRETROVIRAL AGENTS



(57) Abstract

Oligopeptide antiretroviral agents are represented by formula (I), wherein A is a moiety bearing a positive charge and of a size which avoids steric inhibition of binding of said compound to nucleic acid sequences associated with the cellular activity of retroviruses; R₁ is a moiety derived from a dicarboxylic acid; Het is a five-membered heterocyclic moiety; y and z are independently 0, 1, 2 or 3; and x is 0 or 1. These compounds exhibit antiretroviral activity, especially against Human Immunodeficiency Virus (HIV).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				


OLIGOPEPTIDE ANTIRETROVIRAL AGENTSFIELD OF THE INVENTION

This invention relates to oligopeptides which are particularly useful as antiretroviral agents.


5

BACKGROUND OF THE INVENTION

Various oligopeptide derivatives have demonstrated various medicinal uses, such as enzyme inhibitors as disclosed in United States Patent 4,483,850. It is also known that various oligopeptides have anti-tumor activity as disclosed in United States Patents 4,216,208 and 4,314,999. Antibiotic activity of oligopeptides is disclosed in United States Patent 4,454,065. Naturally occurring oligopeptides, netropsin and distamycin, have been discovered as having antiviral and anti-tumor activity. The chemical formulas for netropsin and distamycin are as follows:



Compound 1



Compound 2

SUBSTITUTE SHEET

These oligopeptides are disclosed in Julia, M.,
Préau-Joseph, N., C.R. Hebd-Seances, Acad. Sci. 1963, 257.
1115 and Arcamone, F.; Orezzi, P.G.; Barbier, W.;
Nicolella, V.; Penco, S.; Gazz. Chim. Ital., 1967, 97,
1097.

5

Netropsin and distamycin contain pyrrole moieties
connected by peptide bonds and with side chains, at least
one of which is positively charged; i.e., an amidine
group, or a group of the guanidyl type.



10 Only distamycin has been used as a therapeutic agent
as commercialized and sold under the trade mark
STALLIMYCIN HYDROCHLORIDE in the form of a 1% cream,
ointment or paste. This composition has been used in the
15 treatments of infections produced by herpes simplex,
herpes zoster and vaccinia viruses. Topical application
of distamycin has been limited due to its high
cytotoxicity and a low therapeutic index which in the
instance of treating the herpes virus is about 3.

20 U.S. Patent No. 4,912,199 discloses oligopeptides
containing pyrrole moieties which demonstrated
significantly enhanced antiviral and anticancer activities
as compared to the oligopeptides of the prior art.

According to this invention oligopeptides have been
developed which have significantly enhanced antiretroviral
25 activity compared to prior types of oligopeptides.


SUMMARY OF THE INVENTION

According to an aspect of the invention, a compound represented by the formula I:



wherein A is a moiety bearing a positive charge and of a size which does not inhibit binding of said compound to nucleic acid sequences associated with the cellular action of retroviruses; R₁ is a moiety derived from a dicarboxylic acid or a residue of carbonic acid; Het is a five-membered heterocyclic moiety; y and z are independently 0, 1, 2 or 3, x is 0 or 1, and pharmaceutically acceptable salts thereof, exhibit antiretroviral activity, especially against Human Immunodeficiency Virus and Hepatitis B Virus.

A process for preparing such compounds comprises reacting a compound of the formula (II):



wherein x and y are as defined above; and B is the same as A or is a group with a nitrile, halogen or sulfide substituent; with a dicarboxylic acid of the formula (III):



wherein R₁ is as defined above and X is halogen, imidazolidine or other reactive moiety and converting B to A to form said moiety bearing a positive charge.

SUBSTITUTE SHEET

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing a correlation between DNA binding constants of linked oligopeptides (K_a , -) and observed inhibitory properties expressed in reciprocal ID_{50} values against Moloney Leukemia Virus reverse transcriptase (MLV-RT).

Figures 2-6 are graphs showing anti-HIV activity of several compounds of the present invention.



DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Compounds according to this invention demonstrate significant antiretroviral activity. Although the actual biological mechanism of these compounds which cause antiretroviral activity is not fully understood, it is thought that the activity may be due to the compounds of this invention binding with nucleic acid sequence(s) associated with the cellular action of retroviruses to inactivate such nucleic acids which code for the retroviral activity. It has also been observed that the linked oligopeptides of the present invention are potent inhibitors of Moloney Leukemia Virus (MLV) reverse transcriptase, a potential indicator of anti-HIV activity. See Figure 1.

The compounds of this invention have heterocyclic moieties, which may be the same or different, linked by a dicarboxylic acid derivative. Such linked heterocyclic moieties of this invention have significant unexpected activity compared to unlinked pyrrole moieties such as the naturally occurring netropsin and distamycin.

5


The compounds according to this invention are represented by the following formula:



wherein A is a moiety bearing a positive charge and of a size which does not inhibit binding of said compounds to deoxyribonucleic acid sequences associated with the cellular action of retroviruses; R₁ is a moiety derived from a dicarboxylic acid; Het is a five-membered heterocyclic moiety; R₂, R₃, R₄ and R₅ may be attached to a ring carbon atom or hetero ring atom and are independently selected from C₁-C₆ alkyl and CH₂-O-R₆, where R₆ is a C₁-C₆ alkyl; y and z are independently 0, 1, 2 or 3; x is 0 or 1; and pharmaceutically acceptable salts thereof.

The positively charged moiety at each extremity of the compound and identified as group A is preferably selected from the group of derivatives consisting of an amidine, a guanidine, secondary ammonium salts, sulfonium salts and phosphonium salts.

The selected amidine may have one or both nitrogen atoms of the amidine as a member of a five-membered cyclic structure. More particularly, the amidine derivative is represented by the formula:




30 where p equals 0 to 5 and X is -H, -OH, -NH₂, -CH₃, -C₂H₅, -C₃H₇.

SUBSTITUTE SHEET

6

The selected guanidine for substituent A may be represented by the formula:




where p equals 0 to 5 and X equals -H, -OH, -NH₂, -CH₃, -C₂H₅, -C₃H₇.

10 When A is selected to be a quaternary, tertiary or secondary ammonium salt, it may be represented by the formula:



where p equals 1 to 5 and q equals 0 to 3 and X is an alkyl or alkenyl group of 1 to 3 carbon atoms.

15 When A is selected as a sulfonium salt, it may be represented by the formula:



where p equals 0 to 5 and X and Y are alkyl or alkenyl groups of 1 to 3 carbon atoms.

20 In the heterocyclic moieties, Het may be the same in each moiety or may be different. Preferably, the Het group is selected from the group consisting of a pyrrole, an imidazole, a triazole, a pyrazole, a thiazole, a thiophene, a furan, an oxazole and derivatives thereof.

25 Preferred ring carbon atom substituents are alkyl groups, and especially methyl groups, on the Het moiety, especially on thiazole rings.

SUBSTITUTE SHEET

Preferred Het substituents are N-alkyl pyrrole having 1 to 6 carbon atoms in the alkyl group; N-alkyl imidazole having 1 to 6 carbon atoms in the alkyl group; alkyl pyrazole having 1 to 6 carbon atoms in the alkyl group; and alkyl triazole having 1 to 6 carbon atoms in the alkyl group. Preferably the N-alkyl pyrrole has 1 to 4 carbon atoms in the alkyl group, and especially in N-methyl pyrrole. Also preferred Het substituents are N-linked alkoxymethyl groups. The choice of Het substituents will depend on their cellular uptake ability.

R_2 , R_3 , R_4 and R_5 are linked to the N or C atom of the Het moiety and are independently C_1 - C_6 alkyl or $-CH_2-O-R_6$ where R_6 is C_1 - C_6 alkyl. It has been found that the longer the alkyl group in either structure is, the better the cellular uptake of the compound. The choice of substituent will depend on solubility properties; solubility in pharmacologically acceptable solvents, such as water or DMSO, has been found to be higher with the methoxy substituents.

The linking group R_1 is a derivative from carboxylic acid. R_1 is represented generally by the formula:




where p equals any number from 1 to 22. Alternatively, R_1

O

may be a residue of carbonic acid, namely $-C-$; or R_1 may be a residue of an aromatic dicarboxylic acid. The $-CO-$ groups of the aromatic dicarboxylic acid residues may be in the ortho, meta or para positions on the ring. The aromatic residues may be 5 to 6 C membered rings. The aromatic dicarboxylic acid may also be a six membered heterocyclic ring containing a nitrogen atom.


SUBSTITUTE SHEET

Other alternative structures for the linking group may be a residue of an unsaturated aliphatic dicarboxylic acid of the formula:




5 where q equals any number from 2 to 22.

R₁ may also be a residue of cycloalkane dicarboxylic acids of the formula:



10 where r equals any number from 3 to 7 and optionally may be fused to one or more three to seven C membered rings, preferably fused to one or two three to seven C membered rings.

R₁ may also be a residue of cycloalkane dicarboxylic acids of the formula:



where s equals any number from 3 to 7.

20 In a preferred compound of the present invention, A is a moiety selected from the group consisting of an amidine, a guanidine, secondary ammonium salts, tertiary ammonium salts, quaternary ammonium salts, sulfonium salts and phosphonium salts.


25 In another preferred compound of the present invention, R₂, R₃, R₄ and R₅ are each a C₁-C₆ alkyl or R₂, R₃, R₄ and R₅ are the same and are a C₁-C₆ alkyl group or R₂, R₃, R₄ and R₅ are each a methoxymethyl.

SUBSTITUTE SHEET

In another preferred compound of the present invention, R_1 is

5 $\text{-}\overset{\text{O}}{\parallel}\text{C-}$ or R_1 is a residue of a dicarboxylic acid of the formula $\text{-CO-C}_p\text{H}_{2p}\text{-CO-}$ where p equals 1 to 22. R_1 may also be preferably a residue of a dicarboxylic acid selected from the group consisting of: a residue of an unsaturated aliphatic dicarboxylic acid of the formula $\text{-CO-C}_q\text{-H}_{2q-2}\text{-CO-}$ where q equals 2; a residue of an aromatic dicarboxylic acid; and a residue of a cycloalkane dicarboxylic acid of the formula $\text{-CO-C}_r\text{-H}_{2r-2}\text{-CO-}$ where r equals 3 to 6.

In yet another preferred compound, R_1 is



15 Preferably, R_1 is a dicarboxylic acid residue of cyclopropane, a dicarboxylic acid residue of cyclopentane, or a dicarboxylic acid residue of cyclohexane.

The following are representative examples of the preferred compounds of the present invention.

20 N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] terephthalamide dihydrochloride.

N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] isophthalamide dihydrochloride.

25 N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] fumaramide dihydrochloride.


N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] maleamide dihydrochloride.

30 N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] trans 1,2-cyclobutanamide dihydrochloride.


SUBSTITUTE SHEET

N, N'-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] trans 1,2-cyclobutanamide dihydrochloride.

The compound:




The compound:



SUBSTITUTE SHEET

10/2


The compound:



SUBSTITUTE SHEET

10/3


The compound:



SUBSTITUTE SHEET

10/4

The compound:






SUBSTITUTE SHEET



In cases where R_1 is a dicarboxylic acid derivative of an aliphatic hydrocarbon, the linker is referred to as flexible. Rigid linkers refer to cases in which R_1 is carbonic acid or residues of aromatic, unsaturated aliphatic, cycloalkane and cycloalkene dicarboxylic acids.

5 Most preferred are those compounds in which R_1 is a rigid linker. Examples of the flexible linked and rigid linked oligopeptides are set forth below.





FLEXIBLE LINKED OLIGOPEPTIDES





10








SUBSTITUTE SHEET






- 5
- 10
- 15
- 3 R₁—CO—R₁
 - 4 R₁—COCH₂CO—R₁
 - 5 R₁—CO(CH₂)₂CO—R₁
 - 6 R₁—CO(CH₂)₃CO—R₁
 - 7 R₁—CO(CH₂)₄CO—R₁
 - 8 R₁—CO(CH₂)₅CO—R₁
 - 9 R₁—CO(CH₂)₆CO—R₁
 - 10 R₁—CO(CH₂)₇CO—R₁
 - 11 R₁—CO(CH₂)₈CO—R₁
 - 12 R₁—CO(CH₂)₉CO—R₁
 - 13 R₁—CO(CH₂)₁₀CO—R₁
 - 14 R₂—CO(CH₂)₂CO—R₂
 - 15 R₃—CO(CH₂)₂CO—R₃
 - 16 R₃—CO(CH₂)₆CO—R₃
 - 17 R₃—CO(CH₂)₈CO—R₃
 - 18 R₃—CO(CH₂)₂₂CO—R₃

Rigid Linked Oligopeptides













5



10




14



15


Other preferred compounds include compounds of formula I wherein Het is pyrrole and x is 1; A is:




5

and R_1 is a rigid linker (as defined above).

The heterocyclic moiety of the compounds of this invention may be linked in accordance with various processes by use of the dicarboxylic acid derivatives. In accordance with one aspect of this invention, the process for providing such linkage comprises reacting a compound of the formula:




wherein x and y are as defined above; and B is the same as A or is a group with a nitrile, halogen or sulfide substituent; with a dicarboxylic acid of the formula:



wherein R_1 is as defined above and X is halogen, imidazolidine or other reactive moiety and converting B to A to form said moiety bearing a positive charge.

In the reactants, B may be generally represented by the formula:




where Z is CN^- , hal or XS ; hal is a halogen ion, X is an alkyl or alkenyl group having 1 to 3 carbon atoms, and p equals 0 to 5.

SUBSTITUTE SHEET

16

It is to be appreciated that B may also be identical to A in providing a charge group, for example, a guanidinium end group. In that instance, B has the general formula:




wherein X is an alkyl having 1 to 3 carbon atoms or alkenyl group having 2 or 3 carbon atoms and p equals 0 to 5 and s equals 0 or 1.

10

Compounds of the present invention which are asymmetrical around the linking group (i.e., wherein y and z are different in number) can be prepared by a two-step process, wherein the first step involves coupling a compound of the formula:


15



wherein B, x and z are as defined above, with a dicarboxylic acid of the formula:



wherein R₁ and X are as defined above (this coupling is generally with the use of equimolar amounts of the reactants). This is followed by coupling of a compound of the formula:




wherein B, x and z are as defined above, with the provisions that z is different than y.


According to preferred embodiments of the invention, the following reaction schemes demonstrate preferred chemical pathways to the compounds of this invention having the various desired end groups:




5

A - Preparation of Amidinium End Group






B - Preparation of Guanidinium End Groups




C - Preparation of Ammonium Salt in End Group

13

D - Preparation of Sulfonium Salts

SUBSTITUTE SHEET

Reference may be made to J.W. Lown and K. Krowicki, J. Org. Chem. 1985, 50, 3774 regarding the synthesis of related types of pyrrole moieties such as the synthesis of distamycin. The general synthesis of the compounds according to this invention are based on the total synthesis of distamycin. Dipyrrole or tripyrrole peptides bearing an amino group and a side-chain containing a group (B) which is the nitrile, ammonium or sulfide as represented by the following formula:



are allowed to react at a temperature of -35 to $+10^{\circ}\text{C}$, preferably about -20°C , with a dicarboxylic acid dichloride in the presence of a base or with a diimidazolidine of a dicarboxylic acid to give a bis-amide of the dicarboxylic acid. The resulting compound in the case of nitrile is allowed to react at a temperature of 0 to $+35^{\circ}\text{C}$, preferable $+15^{\circ}$ to $+25^{\circ}\text{C}$, more preferably about $+20^{\circ}\text{C}$, with ethanol in the presence of hydrochloric acid and then at a temperature of 0 to $+35^{\circ}\text{C}$, preferably $+15$ to $+25^{\circ}\text{C}$, more preferably about $+20^{\circ}\text{C}$, with ammonia (Pinner reaction) to generate an amidinium moiety in the final product, as exemplified by the above reaction scheme A. As with reaction scheme D, the sulfide is methylated at a temperature of 0 to $+35^{\circ}\text{C}$, preferable $+15$ to $+25^{\circ}\text{C}$, more preferably about $+20^{\circ}\text{C}$, to produce the corresponding sulfonium salt.

The compounds of formula I, are useful as antiretroviral agents, especially against the Human Immunodeficiency Virus (HIV). Human patients suffering from diseases caused by, for example, HIV, can be treated by administering to the patient a pharmaceutically

SUBSTITUTE SHEET

effective amount of one or more of the present compounds optionally, but preferably in the presence of a pharmaceutically acceptable carrier or diluent. There may be also included pharmaceutically compatible binding agents and/or adjuvant materials. The active materials can also be mixed with other active materials which do not impair the desired action and/or supplement the desired action. The active materials according to the present invention can be administered by any route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, rectally or topically, in a liquid or solid form. For injection purposes, the medium used may be a sterile liquid. As an injection medium, it is preferred to use water which contains the stabilizing agents, solubilizing agents and/or buffers conventional in the case of injection solutions. Desirable additives include, for example, tartrate and borate buffers, ethanol, dimethylsulfoxide, complex forming agents (for example, ethylenediamine tetracetic acid), high molecular weight polymers (for example, liquid polyethylene oxide) for viscosity regulation or polyethylene derivatives of sorbitan anhydrides. Solid carrier materials include, for example, starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acid, high molecular weight fatty acids (such as stearic acid), gelatin, agar, calcium phosphate, magnesium stearate, animal and vegetable fats or solid high molecular weight polymers (such as polyethylene glycol). Compositions suitable for oral administration can, if desired, contain flavoring and/or sweetening agents.

A preferred mode of administration of the compounds of this invention is oral. Accordingly, the compounds may be formulated into capsule form or tablet form.

SUBSTITUTE SHEET

The active materials according to the present invention can be employed in dosages and amounts which are conventional in the art. Thus, the materials can be used at a dosage range in humans of from about 1 to 200 mg/kg total body weight/day. A more preferred range lies between 1-30 mg/kg total body weight/day. The dosages may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

The in vitro anti-HIV screening test results, performed at the United States National Cancer Institute, have shown that 23 of the present compounds are active. Of the fifteen, ten are considered "active", and thirteen are determined "moderately active". Certain of the compounds screened for anti-AIDS activity at the NCI were determined to be "inactive". These compounds were ones wherein the R_1 is $-\text{CO}-(\text{CH}_2)_6-\text{CO}-$ or $-\text{CO}-(\text{CH}_2)_8-\text{CO}-$, A is amidine, x is 1, Het is methylpyrrole, and y and z are 1, as well as compounds 9, 11, 15, 16, 18 and 37.

The therapeutic index of a compound is determined by dividing the inhibitory or lethal concentration for 50% of the population (IC_{50}) by the effective concentration for 50% of the population (EC_{50}). The therapeutic indexes for the particularly active compounds of the present invention range from 1.46 to 161.

As used in this invention, antiretroviral activity refers to the ability of a compound to inhibit the growth of a retrovirus. The retrovirus of primary importance with respect to the present invention is HIV. However, the present compounds may also exhibit antiretroviral activity towards other retroviruses as would be apparent by the suspected mechanism of action and other viruses which replicate or exhibit reverse transcription.

SUBSTITUTE SHEET

The compounds of the present invention should also be therapeutically effective in the treatment of hepatitis B viral infection in mammals, especially humans. Similar to retroviruses (including HIV-1), the hepatitis B virus replicates by reverse transcription. In addition, hepatitis B virus putative viral polymerase share amino acid homology with reverse transcriptase of retroviruses and a comparison of the thirteen (13) hepadnavirus isolates determined that other conserved areas showing homolgy to corresponding regions of Type C retro virus. Miller et al., Proc.Natl.Acad.Sci. USA, Vol 83:2531-2535 (1986).

Since it is theorized that the activity of the compounds of the present invention may be due to the compounds binding with nucleic acid sequence(s) associated with the cellular action of retroviruses to inactivate such nucleic acids which code for the retroviral activity, the compounds are likely to inhibit binding with nucleic acid sequence(s) of the hepatitis B virus associated with the cellular action of reverse transcription to inactivate such nucleic acids which code for the retroviral-like activity. Therapeutically effective anti-hepatitis B dosages would be the same as anti-HIV-1 dosage levels as well as would the routes of administration.


The ability of a compound to inhibit HIV may be measured by various experimental techniques. One such technique, currently employed by the United States National Cancer Institute to screen potential anti-HIV compounds, involves the inhibition of the killing of HIV-infected T₄ lymphocytes. Compounds of the present invention have been tested for anti-HIV-1 activity in the NCI protocol; however, one skilled in the art would appreciate that the compounds should exhibit activity against HIV-2 as well.

SUBSTITUTE SHEET

Preferred embodiments of the invention are exemplified in the following Examples which are in no way to be construed as limiting the scope of the appended claims.

5 EXAMPLE 1

Compound of the formula I, where $x=1$, y and z each are 1;



R_1 equals $-COCH_2CH_2CO-$, was prepared. 1-Methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)-pyrrole-2-carboxamidopropionitrile (105 mg, 0.33 mmole) and 1-Pr₂EtN (diisopropylethylamine) (65 μ l, 0.16 mmole) in anhydrous THF (1 ml) was added and the mixture was allowed to reach room temperature. The solvents were evaporated to dryness and water was added. The resulting solid was collected and washed with hot MeOH to give 90 mg (77% yield) of the product m.p. 297°C. The latter was suspended in anhydrous EtOH and saturated with HCl while cooling. After 1.5 hours at room temperature, the solvent was removed in vacuo and the residue was washed with dry ether then ethanol was added followed by some ammonia condensed into the solution. After 1 hour at room temperature, the solvent was removed and the residue was washed with MeOH, EtOH and hexane to afford 80 mg of a solid. Recrystallization from a small volume of water gave a jelly-like precipitate which was washed with EtOH, hexane and dried to give 35 mg (35% yield) of pure product m.p. 283-285°C dec. ¹H-NMR (DSMO-d₆): δ 2.60 (m, 4H), 3.60 (m, 2H), 3.83 (s, 6H), 6.92 (d, 2H), 7.18 (d, 2H), 8.25 (t,

15

20

25


30

24

1H), 8.70 (bs, 2H), 9.02 (bs, 2H), 9.93 and 9.97 (2s, 2H),
 MS-FAB (m/z): 745 (M-Cl-HCl)⁺: Anal. Calcd. for
 C₃₄H₄₆Cl₂N₁₄O₆: C, 49.9, H, 5.7, N, 24.0, Cl, 8.7, Found:
 C, 50.3, H, 6.05, N, 22.9, Cl, 8.7.

5 EXAMPLE 2

Compound of the formula I, where x equals 1; y and z
 are each equal to 1;



R₁ equals -CO- was prepared. 1-Methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)-pyrrole-2-carboxamidopropionitrile (315 mg, 1 mmole) and 81 mg of 1,1'-carbonyldiimidazole were dissolved in 10 ml of anhydrous CH₃CN and refluxed under argon for 5 minutes. A solid forms which was collected to give 302 mg (88.6% yield) of the pure product was treated with HCl in EtOH and then NH₃ (as in Example 1). After the reaction was completed, the mixture was decanted from an insoluble residue. The solvent was removed in vacuo and the residue was dissolved in 4 ml of MeOH and an excess of CH₃CN was added to precipitate the product which was collected and washed with 1 ml of cold water whereupon it became jelly-like. The product was redissolved in MeOH and reprecipitated with CH₃CN to give 216 mg (57% overall yield) of the pure compound m.p. 211-215°C; ¹H-NMR (DMS)-d₆: δ 2.64 (t, 2H), 3.52 (q, 2H), 3.84 (s, 6H), 6.82, 6.94, 7.03, 7.20 (4d, 4H), 8.25 (t, 1H), 8.73 (2s, 3H), 9.05 (s, 2H), 9.88 (s, 1H), MS-FAB: 690 (M-Cl-HCl)⁺. Anal. Calcd. for C₃₁H₄₂Cl₂N₁₄O₅: C, 48.9, H, 5.6, Cl, 9.3, N, 25.7; Found C, 48.5, H, 5.7, Cl, 9.7, N, 25.3.

SUBSTITUTE SHEET

EXAMPLES 3(A) AND (B)

The following Examples illustrate the effect of altering the steric size of the terminal group (in these cases trialkylammonium) on the basic Het block of the general formula on the nucleic acid binding and antiviral efficacy. The effects were demonstrated on deoxyribonucleic acid to show that steric hindrance in the terminal group in DNA binding generally reduces antiviral activity of the compounds.

- 10 (A) 1-Methyl-4-(1-methyl-4-trimethylammonium-acetamidopyrrole-2-carboxamido)pyrrole-2-carboxyamidopriopionamidine chloride hydrochloride

A solution of the precursor 1-methyl-4-(1-methyl-4-trimethylammonium-acetamido-pyrrole-2-carboxamido)pyrrole-2-carboxyamidopriopionitrile chloride (347 mg, 0.07 mmoles) in 5 ml of absolute ethanol was treated with dry hydrogen chloride with cooling. After 2 hours, the solvent was removed in vacuo, 5 ml of absolute ethanol was added and dry NH_3 gas passed into the solution. The solid dissolved during 2 hours at room temperature, then the solution was evaporated to dryness and extracted with hot isopropyl alcohol (100 ml). The extract was concentrated to ca. 10 ml, acetone added and the resulting precipitate collected, washed with acetone, and dried to vacuo to give the product, 300 mg (85% yield) as an amorphous hygroscopic solid, no definite m.p.; $^1\text{H-NMR}$ (DMSO-d_6): δ 2.67 (t, 2H), 3.31 (s, 9H), 3.52 (q, 2H), 3.82 and 3.87 (2s, 6H), 4.44 (s, 2H), 6.97 (d, 1H), 7.02 (d, 1H), 7.24 (d, 1H), 7.29 (d, 1H), 8.31 (t, 1H), 8.82 (bs, 2H), 9.72 (bs, 2H), 10.06 (s, 1H), 11.23 (s, 1H), IR (Nujol) ν_{max} : 1260, 1377, 1405, 1453, 1531, 1582, 1643, 1685, 3247 cm^{-1} ; MS-FAB (m/z) 430 (M-HCl-Cl) $^+$.

Sulfate. The sulfate corresponding to the product was prepared in order to obtain an analytically pure sample by precipitation from a methanolic solution of the above compound by means of a large excess of
5 tetraethylammonium sulfate, m.p. 295°C: IR (Nujol) ν_{\max} : 1255, 1377, 1405, 1462, 1525, 1560, 1580, 1640, 1670, 3280 cm^{-1} ; MS-FAB (m/z) 431 (M-HSO₄)⁺, 529 MH⁺; Anal. Calcd. for C₂₀H₃₂N₈O₇S (528.59), C, 45.4, H, 6.1, N, 21.1, S, 6.1. Found: C, 45.0, H, 6.0, N, 20.7, S, 5.8.

10 (B) 1-Methyl-4-(1-methyl-4-trimethylammonium-acetamidopyrrole-2-carboxamido)pyrrole-2-
carboxyamidopropionamidine chloride hydrochloride

A solution of the precursor analogous to that of Example 3(A) (173 mg, 035 mmoles) in 10 ml of absolute
15 ethanol was treated with dry hydrogen chloride with cooling. After 2 hours, the solvent was removed in vacuo and the residue dissolved in 10 ml of absolute ethanol and treated with an excess of dry ammonia. After 2 hours at
20 room temperature, the solvent was removed in vacuo and the residue dissolved in 5 ml of isopropyl alcohol; then the product was precipitated with ether. The solid was collected, washed with ether and dried at 100° in vacuo to
afford the product 103 mg (59% yield) m.p. 180° (dec);
25 ¹H-NMR (DMSO-d₆): δ 1.32 (t, 9H), 2.67 (t, 2H), 3.54 (m, 8H), 3.83 and 3.88 (2s, 6H), 4.32 (s, 2H), 6.96 (d, 1H), 7.01 (d, 1H), 7.21 (d, 1H), 7.30 (d, 1H), 8.28 (t, 1H) 8.80 and 9.10 (bs, 4H), 10.03 (s, 1H), 11.47 (s, 1H), IR (Nujol): 1376, 1404, 1462, 1531, 1581, 1646, 1684, 3250 cm^{-1} ; MS-FAB (m/z): 981 (2M-HCl-Cl)⁺, 473 (M-HCl-Cl)⁺.

30 The activities of Examples 3(A) and 3(B) expressed as minimum inhibitory concentration ($\mu\text{g/ml}$) against vaccinia virus were 20 and 300 respectively illustrating the effects of steric hindrance in DNA binding on reducing agent activity. The larger the terminal group, as

SUBSTITUTE SHEET

demonstrated by compound 3(B), the lesser the activity; hence the terminal group is of a selected size which will maintain nucleic acid sequence bonding desired antiretroviral activity.

- 5 The compound numbers referred to in the following examples correspond to the numbered structures in the "Detailed Description of the Invention" section.

EXAMPLE 4

- 10 (A) 1-Methyl-4-[1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido]pyrrole-2-carboxamidopriopionitrile (Intermediate Compound)

- 15 1-Methyl-4-[1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido]pyrrole-2-carboxamidopriopionitrile (Lown, W.J. and Krowicki, K., J. Org. Chem. Vol. 50, p. 3774 (1985) and Krowicki, K. and Lown, W.J., J. Org. Chem., Vol. 52, p. 3493 (1987) (420 mg, 0.9 mmol) was reduced over 5% palladium on charcoal (260 mg) in a mixture of DMF (15 ml) and methanol (5 ml) at 45°. After the reduction the solvents were evaporated
- 20 under reduced pressure. The residue was dissolved in a small amount of acetonitrile (2 ml) and an excess of ethyl acetate (20-30 ml) as added to precipitate some impurities. The filtrate was treated with an excess of hexane to precipitate a white pure product 9 (250 mg, 63.5% yield), m.p. 155-160°. ¹H-NMR (DMSO-d₆): δ 2.74 (t, 2H), 3.42 (q, 2H), 3.76 (s, 3H), 3.85 and 3.87 overlapped with a bs (3s, 8H), 6.27 (d, 1H), 6.40 (d, 1H), 6.95 (d, 1H), 7.04 (d, 1H), 7.24 (2d, 2H), 8.37 (t, 1H) 9.66 (s, 1H), 9.96 (s, 1H); IR (nujol): 1260, 1377, 1403,
- 25 1464, 1529, 1582, 1646, 2245, 3120, 3310 cm⁻¹; MS m/z 436.1981 (calcd. 436.1983). Analysis Calcd. for C₁₉H₂₆ClN₆O₃: C 52.3, H 6.0, Cl 8.1, N 22.5. Found: C 52.3, H 6.0, Cl 7.9, N 22.0.
- 30

EXAMPLE 5

(A) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido
(3-proprionitrile)-4-pyrrole]-4-pyrrolyl)succinamide

5 The intermediate compound (105 mg, 0.33 mmol) and i-
Pr₂EtN (65 μ L, 0.37 mmol) were dissolved in anhydrous
acetonitrile (5 ml) and cooled to -20°C. Succinyl
chloride (18 μ L, 0.16 mmol) in anhydrous THF (1 ml) was
added. The mixture was allowed to reach ambient
10 temperature. The solvents were evaporated to dryness,
water was added, and the resulting solid was collected and
washed with hot MeOH. The product was dissolved in DMF
and when placed on a TLC plate (SiO₂) with CHCl₃ + 15%
MeOH system it gave one spot. For analytical purposes,
15 the product was purified by dissolution in a small amount
of DMF and precipitation with a large amount of EtOH to
give 90 mg (77%) of 15 m.p. 292°. ¹H-NMR (DMSO-d₆): δ
2.58 (s, 4H) 2.74 (t, 4H), 3.42 (q, 4H), 3.83 (2s, 12H),
6.86, 6.93, 7.17 and 7.22 (4d, 2H each), 8.35 (t, 2H),
9.89 (s, 4H); IR (nujol): 1376, 1401, 1447, 1465, 1511,
20 1535, 1585, 1645, 2245, 3120, 3304 cm⁻¹; MS (m.z. rel.
int.): 396.1543 (9.98) for C₁₉H₂₀N₆O₄ which is (O=C-CH-
M_{1/2})⁺. Analysis Calcd. for C₃₄H₃₈N₁₂O₆: C 57.5, H 5.4,
N 23.6. Found: C 57.8, N 5.4, N 23.3.

25 (B) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido
(3-proprionamidine)-4-pyrrole]-4-pyrrolyl)succinamide
dihydrochloride (Compound 5)

A suspension of the previous product (130 mg, 0.18
mmol) in 15 ml anhydrous EtOH was saturated with HCl with
cooling. After 1.5 hr. at r.t., the solvent was
30 evaporated under reduced pressure. The residue was washed
with dry ether, then ethanol was added followed by some
NH₃ condensed into the vessel. After 1 hr at r.t. the
solvents were removed and the residue was washed with
MeOH, EtOH and hexane to give 116 mg of a solid. The

latter was examined by TLC (SiO_2) with MeOH and a drop of formic acid and indicated formation of the product ($R_f = 0.3$) containing some more polar impurity. Recrystallization from a small amount of water gave a gel-like precipitate which was washed with EtOH and hexane and dried give to 50 mg (34% of pure 5a, m.p. 283-5° dec. $^1\text{H-NMR}$ (DMSO-d_6): δ 2.60 (m, 8H) 3.50 (m, 4H), 3.83 (s, 12H), 6.92 (d, 4H), 7.18 (d, 4H), 8.25 (t, 2H), 8.70 (bs, 4H), 9.02 (bs, 4H) 9.93 and 9.97 (2s, 4H); IR (nujol): 1352, 1377, 1464, 1521, 1576, 1638, 1700, 3260 cm^{-1} ; MS-FAB (m/z): 745 (M-Cl-HCl)⁺. Analysis Calcd. for $\text{C}_{34}\text{H}_{46}\text{Cl}_2\text{N}_{14}\text{O}_6$: C 49.94, H 5.67, N 23.98, Cl 8.67. Found: C 50.3, H 6.05, N 22.90, Cl 8.75.

EXAMPLE 6

(A) N,N' -Di(1-methyl-2-[1-methyl-2-carboxamido (3-proprionitrile)-4-pyrrolo]-4-pyrrolyl)malonamide

The intermediate compound (315 mg, 1 mmol), malonic acid (52 mg, 0.5 mmol) and DCC 206 mg, 1 mmol) were stirred in acetonitrile (6 ml) for 2 hr at room temperature and finally the mixture was heated briefly to boiling to complete the reaction. A solid which contained dicyclohexylurea was collected and the filtrate was extracted with DMF. The DMF solution was treated with water and the solid formed was recrystallized from a mixture of acetonitrile (2 ml) and methanol (2 ml) to give pure compound (140 mg, 40% yield), m.p. 225-30°. $^1\text{H-NMR}$ (DMSO-d_6): δ 2.73 (t, 2x2H), 2.40 (q+s overlapped, 2x2H+2H), 3.83 and 3.86 (2s, 2x6H), 6.91 (2d, 2x2H), 7.18 and 7.22 (2d, 2x2H), 8.35 (t, 2x1H), 9.91 (s, 2x1H), 10.09 (s, 2x1H); IR (nujol): 1200, 1264, 1290, 1376, 1401, 1464, 1511, 1532, 1585, 1638, 1662, 2250, 3120, 3305 cm^{-1} ; MS-FAB (m/z): 697 (MH^+). Analysis Calcd. for $\text{C}_{33}\text{H}_{36}\text{N}_{12}\text{O}_6$: C 56.9, H 5.2, N 24.1. Found: C 56.6, H 5.4, N 23.9.

SUBSTITUTE SHEET

(B) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido
(3-proprionamide)-4-pyrrole]-4-pyrrolyl)malonamide
dihydrochloride (Compound 4)

5 The compound of the previous synthesis (160 mg, 0.23 mmol) was suspended in dry ethanol and the mixture was saturated with dry hydrogen chloride. After 1.5 hr at room temperature, the solvent was removed under reduced pressure. The residue was treated with dry ethanol and dry ammonia. After 1 hr the solution was decanted from
10 undissolved material and evaporated to dryness. The residue was dissolved in 2 ml of boiling water and an excess of acetonitrile was added to the hot solution. The precipitate was collected and washed with a small amount of water. The operation was repeated and pure compound 4
15 was collected, 100 mg (59% yield), m.p. 218-224°. The compound, if crystallized from water, precipitates in the form of a jelly. ¹H-NMR (DMSO-d₆): δ 2.63 (t, 2x2H), 3.35 (s overlapped with the peak of water), 3.50 (q, 2x2H), 3.80 and 3.83 (2s, 2x6H), 6.93 (s, 2x2H), 7.20 (s, 2x2H), 8.26 (t, 2x1H), 8.90 (bs, 2x4H), 9.96 (s, 2x1H),
20 10.28 (s, 2x1H). D₂O exchange experiment showed the presence of malonyl protons at δ 3.30. IR (nujol): 1260, 1377, 1405, 1463, 1535, 1580, 1645, 3100, 3270 cm⁻¹; MS-FAB (m/z) 731 (M-Cl-HCl)⁺. Analysis Calcd. for
25 C₃₃H₄₄N₁₄O₆Cl₂: C 49.3, H 5.5, N 24.4, Cl 8.8. Found: C 49.0, H 5.7, N 27.0, Cl 9.0.

EXAMPLE 7

(A) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido
(3-proprionitrile)-4-pyrrole]-4-pyrrolyl)urea

30 The intermediate compound (365 mg, 1.16 mmol) and 1,1'-carbonyldiimidazole (94 mg, 0.58 mmol) were allowed to react in boiling acetonitrile (3 ml). A solid which formed was collected, washed with acetonitrile to give 150 mg (88.6% yield) of pure product, m.p. 296-7°. ¹H-NMR

3.88 (s, 6H), 6.80 (d, 2H), 6.92 (d, 2H), 7.02 (d, 2H),
7.21 (d, 2H), 8.12 (s, 2H), 8.25 (t, 2H), 9.81 (s, 2H); IR
(nujol): 1199, 1217, 1252, 1378, 1409, 1436, 1465, 1504,
1544, 1589, 1621, 1653, 1672, 2240, 3270, 3424 cm^{-1} ; MS-
5 FAB (m/z): 655 (MH^+). Analysis Calcd.: C 56.9, H 5.2, N
25.7. Found: C 56.6, H 5.4, N 25.5.

(B) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido
(3-propionamidine)-4-pyrrole]-4-pyrrolyl)urea
dihydrochloride (Compound 3)

10 The compound synthesized in the previous step (116
mg, 0.25 mmol) was suspended in dry ethanol and the
solution saturated with HCl. After 2 hr the solvent was
evaporated in vacuo and the residue treated with dry
ammonia in ethanol for 1 hour. The mixture was decanted
15 from an insoluble residue and the solution evaporated to
dryness. The residue was dissolved in 2 ml of methanol
and an excess of acetonitrile was added to precipitate the
product. The latter was collected and washed with 1 ml of
water when it became jelly-like. It was redissolved in
20 methanol and precipitated with acetonitrile to give the
compound (3) (117 mg, 61.6% yield), m.p. 211-215°. $^1\text{H-NMR}$
(DMSO- d_6): δ 2.64 (t, 4H), 3.52 (q, 4H), 3.84 (2s, 12H),
6.82 (d, 2H), 6.94 (d, 2H), 7.03 (d, 2H), 7.20 (d, 2H),
8.73 (2s overlapped, 6H), 9.05 (s, 4H), 9.88 (s, 2H); IR
25 (Nujol): 1264, 1377, 1402, 1439, 1489, 1531, 1583, 1640,
1689, 3088, 3279 cm^{-1} ; MS-FAB (m/z): 690 (M-Cl-HCl) $^+$.
Analysis Calcd. for $\text{C}_{31}\text{H}_{42}\text{Cl}_2\text{N}_{14}\text{O}_5$: C 48.9, H 5.6, Cl
9.3, N25.7. Found: C 48.5, H 5.7, Cl 9.7, N 25.3.

SUBSTITUTE SHEET

EXAMPLE 8(A) N,N'-Di(1-methyl-2-carboxamido(3-proprionitrile)-4-pyrrole)-4-pyrrolyl)adipamide

Adipic acid (29.2 mg, 0.2 mmol) in acetonitrile (0.5 ml) was treated with pivaloyl chloride (50 μ L, 0.4 mmol) and Hunig's base (160 μ L, 0.9 mmol) and then compound 7 (126 mg, 0.42 mmol) in DMF (0.5 ml) was added. After a half hour at room temperature the mixture was evaporated to dryness under reduced pressure. The residue was washed with water and hot acetonitrile. The solid was dissolved in hot DMF and precipitated with an excess of acetonitrile to give the compound (95 mg, 61% yield), m.p. 244-46° dec. $^1\text{H-NMR}$ (DMSO- d_6): δ 1.60 (s, 4H), 2.27 (s, 4H), 2.74 (t, 4H), 3.40 (q, 4H), 3.83 (2s, 12H), 6.86 (s, 2H), 6.93 (s, 2H), 7.17 (s, 2H), 7.22 (s, 2H), 8.38 (t, 2H), 9.82 (s, 2H), 9.91 (s, 2H); IR (Nugol): 1376, 1400, 1464, 1513, 1533, 1585, 1641, 2258, 3294 cm^{-1} ; MS-FAB (m/z): 738 (M^+), 739 (MH^+); Analysis Calcd. C 58.5, H 5.7, N 22.7. Found: C 58.9, H 5.9, N 22.5.

(B) N,N'-Di(1-methyl-2-[1-methyl-2-carboxamido(3-proprionamidine)-4-pyrrole]-4-pyrrolyl)adipamide dihydrochloride (Compound 7)

The compound synthesized in the previous step (320 mg, 0.43 mmol) was treated under Pinner reaction conditions as in Example 3 above. After evaporation of solvents, water (3.5 ml) was added and a crystalline substance was collected to give (7) (215 mg, 58.7% yield), m.p. 195-6°. $^1\text{H-NMR}$ (DMSO- d_6): δ 1.60 (s, 4H), 2.27 (s, 4H), 2.62 (t, 4H), 3.52 (q, 4H), 3.80 (2s, 12H), 6.88 (d, 2H), 6.95 (d, 2H), 7.18 and 7.20 (2d, 4H), 8.25 (t, 2H), 8.70 (s, 4H), 9.00 (s, 4H), 9.00 (s, 4H), 9.92 (s, 2H); IR

SUBSTITUTE SHEET

(Nujol): 1208, 1261, 1377, 1404, 1463, 1531, 1579, 1641, 1691, 3256 cm^{-1} ; MS-FAB m/z 773 $(\text{M}-\text{HCl}-\text{Cl})^+$; Analysis Calcd.: C 51.1, H 6.0, N 23.2, Cl 8.4. Found: C 50.9, H 6.2, N 23.6, Cl 8.8.

5 EXAMPLE 9

(A) N,N' -Di(1-methyl-2-[1-methyl-2-carboxamido(3-propionitrile)-4-pyrrole]-4-pyrrolyl)maleimide

10 The intermediate compound (158 mg, 0.5 mmol) and maleic anhydride (49 mg, 0.5 mmol) were heated in acetonitrile (5 ml) at 50° for 3 minutes. Another portion of the intermediate compound (158 mg) was added and the solution was evaporated to dryness. The residual solid was dissolved in DMF (2 ml) and DCC (103 mg, 0.5 mmol) was added, and the mixture was set aside overnight at room temperature. Two drops of water were added and the solution was filtered. Then an excess of water precipitated the crude product. The product was collected and chromatographed on silica gel with chloroform and 15% of methanol providing yellow fractions. These were combined and evaporated, and the residue recrystallized from acetone to give the product (100 mg, 56.5% yield), m.p. 250-2°. Analytical data for this and related compounds is given in Table I.

25 (B) N,N' -Di(1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole)-4-pyrrolyl)maleimide dihydrochloride
(Compound 14)

30 The product obtained in the previous step (170 mg, 0.24 mm) was treated under Pinner reaction conditions as in Example 3. The completed reaction mixture was evaporated to dryness and the residue dissolved in ethanol. Controlled addition of isopropanol provided selective precipitation of impurities. The mother liquor was evaporated and the residue was dissolved in methanol

SUBSTITUTE SHEET

and precipitation with acetonitrile gave pure compound (14) (166 mg, 85% yield), m.p. 217°.

EXAMPLE 10

- 5 (A) N,N'-Di{1-methyl-2-[1-methyl-2-carboxamido(3-propionitrile)-4-pyrrole]-4-pyrrolyl}trans-cyclopropyldicarboxamide (Compound 8a)

10 The synthesis and characterization of compounds 3, 4 and 5 have been reported (Krowicki, K. et al, J. Med. Chem., Vol. 31, p. 341 (1988)). Trans-cyclopropyldicarboxylic acid (59 mg, 0.45 mmole) and 1,1'-carbonyldiimidazole (146 mg, 0.7 mmole) in acetonitrile (2.5 ml) were heated under reflux until the evolution of carbon dioxide ceased. To the cooled solution the appropriate amine (284 mg, 0.9 mmole) and 0.8 ml of DMF
15 were added and the mixture was stirred for 2 hr at room temperature (the product partially precipitated) and was evaporated to dryness under reduced pressure. The residue was washed with acetonitrile, aqueous K₂CO₃ then water to give 8a, 289 mg (88.6% yield) m.p. 312° dec.

- 20 (B) N,N'-Di{1-methyl-2-[1-methyl-2-carboxamide(3-propionamidine)-4-pyrrole]-4-pyrrolyl}trans-cyclopropyldicarboxamide dihydrochloride (Compound 8b)

25 Compound 8a (216 mg, 0.3 mmole) was treated under Pinner reaction conditions as described previously. The final reaction mixture was evaporated to dryness and the residue was extracted with hot propanol (150 ml). The extract was evaporated to dryness and the residue dissolved in methanol 1 ml, and an excess of acetonitrile
30 was added to precipitate the product 8b, 170 mg (68.5% yield) m.p. 210° (softens).

SUBSTITUTE SHEET

EXAMPLE 11

Commercially available acid chlorides for the linker groups were used directly without further purification. Otherwise, the appropriate acid chlorides were prepared from the acids according to the following procedure: An acid and a drop of dimethylformamide was heated in thionyl chloride (5 to 10 mole in excess) to 55-65°C for 30 to 45 min until a homogeneous liquid was obtained. The excess of the chlorinating agent was removed by evaporation. A small amount of methylene chloride was added to the crude acid chloride then evaporated. The diacid dichloride was then dissolved in methylene chloride or THF and aliquots were taken and used for coupling reactions.

EXAMPLE 12

Distamycin A (50 mg, 0.09 mmol) was dissolved in 4 mL of methanol. To this yellow solution was added 100 µL of concentrated hydrochloric acid. The solution was stirred for 6-8 h and the reaction progress was followed by TLC (methanol:acetic acid, 100:5). The solvent was evaporated and the crude product was redissolved in methanol and precipitated with ether. The product was recrystallized in this way twice more. The supernatant was decanted and the residual solid was dried in vacuo. The final product was obtained as an off-white solid 50 mg (89% yield).

EXAMPLE 13Bis-distamycin (Compound 15)

A solution of succinyl dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 µL, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 µL, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether.

The final product was obtained as a light yellow solid in 68% yield. m.p. 210°C; ¹H-NMR, 2.48 (COCH₂CH₂CO, 4H, s), 2.56 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.50 (2xCONHCH₂, 4H, q, J = 6 Hz), 3.80 (2xNCH₃, 6H, s), 3.82 (2xNCH₃, 6H, s), 3.83 (2xNCH₃, 6H, s), 6.90 (2xpy-CH, 2H, d, J = 2 Hz), 6.94 (2xpy-CH, 2H, d, J = 2 Hz), 7.04 (2xpy-CH, 2H, d, J = 2 Hz), 7.14 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.22 (2xpy-CH, 2H, d, J = 2 Hz), 8.24 (2xCONHCH₂, 2H, tr, J = 6 Hz), 8.74 [2xC(NH₂)₂Cl, 4H, s], 9.04 [2xC(NH₂)₂Cl, 4H, s], 9.93 (5xpy-NHCO, 5H, s), 9.96 (py-NHCO, 1H, s); MS (FAB), 989 (M-2xCl-H, 0.34).

EXAMPLE 14

Bis-distamycin (Compound 16)

A solution of hexan-1,6-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 µL, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 µL, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 78% yield. m.p., 210°C; ¹H-NMR, 1.28 (4,5-suber-CH₂, 4H, m), 1.57 (3,6-suber-CH₂, 4H, m), 2.23 (2m7-suber-CH₂, 4H, tr, J = 7 Hz), 2.63 (2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz), 3.49 (2xCONHCH₂, 4H, m), 3.80 (2xNCH₃, 6H, s), 3.81 (2xNCH₃, 6H, s), 3.83 (2xNCH₃, 6H, s), 6.88 (2xpy-CH, 2H, d, J = 2 Hz), 6.94 (2xpy-CH, 2H, d, J = 2 Hz), 7.05 (2xpy-CH, 2H, d, J = 2 Hz), 7.15 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.23 (2xpy-CH, 2H, d, J = 2 Hz), 8.25 (2xCONHCH₂, 2H, m), 8.72 [2xC(NH₂)₂Cl, 4H, s], 9.03 [2xC(NH₂)₂Cl, 4H, s], 9.86 (2xpy-NHCO, 2H, s), 9.92 (4xpy-NHCO, 4H, s); MS (FAB), 1045 (M-2xCl-H, 0.38).

SUBSTITUTE SHEET

EXAMPLE 15**Bis-distamycin (Compound 17)**

A solution of octan-1,8-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and dissiopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min. a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 65% yield. m.p., 198-202°C; $^1\text{H-NMR}$, 1.26 [(4,5,6,7-seba-CH₂, 8H, m), 4H, tr, J = 6 Hz], 1.55 [(3,8-seba-CH₂), 4H, m], 2.22 (2,9-seba-CH₂), 4H, tr, J = 8 Hz], 2.61 [2xCH₂C(NH₂)₂Cl, tr, J = 6 Hz], 3.48 (2xCONHCH₂, 4H, m), 3.80 (2xNCH₃, 6H, s), 3.81 (2xNCH₃, 6H, s), 3.83 (2xNCH₃, 6H, s), 6.89 (2xpy-CH, 2H, d, J = 2Hz), 6.95 (2xph-CH, 2H, d, J = 2Hz), 7.05 (2xpy-CH, 2H, d, J = 2 Hz), 7.15 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.22 (2xpy-CH, 2H, d, J = 2 Hz), 8.23 (2xCONHpy-2H, m), 8.65 [2xC(NH₂)₂Cl, 4H, s], 8.99 [2xC(NH₂)₂Cl, 4H, s], 9.82 (2xpy-NHCO, 2H, s), 9.91 (4xpy-NHCO, 4H, s); MS (FAB), 1074 (m-2xCl-H, 0.08).

EXAMPLE 16**Bis-distamycin (Compound 18)**

A solution of docosane-1,22-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and dissiopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a

light yellow solid in 73% yield. m.p., 215°C; $^1\text{H-NMR}$, 1.23 (4,5,...20,21-tetraco- CH_2 , 36H, s), 1.55 (3,22-tetraco- CH_2 , 4H, m), 2.21 (2,23-tetraco- CH_2 , 4H, tr, $J = 7$ Hz), 2.62 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J = 6$ Hz], 3.50 (2 $\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 3.80 (2 $\times\text{NCH}_3$, 6H, s), 3.82 (2 $\times\text{NCH}_3$, 6H, s), 3.84 (2 $\times\text{NCH}_3$, 6H, s), 6.89 (2xpy-CH, 2H, d, $J = 2$ Hz), 6.94 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.05 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.15 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.19 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.23 (2xpy-CH, 2H, d, $J = 2$ Hz), 8.25 (2 $\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 8.72 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, s], 9.02 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, s], 9.83 (2xpy-NHCO, 2H, s), 9.92 (4xpy-NHCO, 4H, s); MS (FAB), 1270 (M-2xCl-H, 0.10).

EXAMPLE 17**15 Bis-distamycin (Compound 29)**

A solution of benzene-1,4-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μL , 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μL , 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether.

25 The final product was obtained as a light yellow solid in 77% yield. m.p., >300°C; $^1\text{H-NMR}$, 2.63 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J = 6$ Hz], 3.50 (2 $\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 3.82 (2 $\times\text{NCH}_3$, 6H, s), 3.86 (2 $\times\text{NCH}_3$, 6H, s), 3.90 (2 $\times\text{NCH}_3$, 6H, s), 6.97 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 7.09 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 7.15 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 7.20 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 7.26 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 7.38 (2xpy-CH, 2H, d, $J = 1.6$ Hz), 8.10 (aromatic-CH, 4H, s), 8.25 (2 $\times\text{CONHCH}_2$, 2H, tr, $J = 6$ Hz), 8.65 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, s], 9.01 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, s], 9.95 (2xpy-NHCO, 2H, s), 10.03 (2xpy-NHCO, 2H, s), 10.57 (2xpy-NHCO, 2H, s); (CD_3OD), 2.71 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J =$

SUBSTITUTE SHEET

7 Hz], 3.65 (2xCONHCH₂, 4H, tr, J = 7 Hz), 3.87 (2xNCH₃, 6H, s), 3.91 (2xNCH₃, 6H, s), 3.95 (2xNCH₃, 6H, s), 6.90 (2xph-CH, 2H, d, J = 1.8 Hz), 6.98 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.07 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.16 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.20 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.34 (2xpy-CH, 2H, d, J = 1.8 Hz), 8.04 (aromatic-CH, 4H, s); MS (FAB), 1037 (M-2xCl-H, 0.05).

EXAMPLE 18Bis-distamycin (Compound 30)

10 A solution of benzene-1,3-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and dissiopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a
15 solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in
20 68% yield. m.p., 240°C; ¹H-NMR, 2.61 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.48 (2xCONHCH₂, 4H, tr, J = 6 Hz), 3.80 (2xNCH₃, 6H, s), 3.86 (2xNCH₃, 6H, s), 3.91 (2xNCH₃, 6H, s), 6.97 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.09 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.16 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.20 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.25 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.38 (2xpy-CH, 2H, d, J = 1.6 Hz), 7.66 (5-aromatic-CH, 1H, tr, J = 7.5 Hz), 8.10 (4,6-aromatic-CH, 2H, d, J¹ = 8 Hz); 8.21 (2-aromatic-CH, 1H, br, s); 8.21 (2xCONHCH₂, 2H, br, s), 8.58 [2xCY₂C(NH₂)₂Cl, 4H, tr, J =
25 7 Hz], 3.64 (2xCONHCH₂, 4H, tr, J = 7 Hz), 3.88 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 3.94 (2xNCH₃, 6H, s), 6.89 (2xpy-CH, 2H, d, J = 1.8 Hz), 6.97 (2xph-CH, 2H, d, J = 1.8 Hz), 7.07 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.20 (2xpy-CH, 2H, d, J = 1.8 Hz), 7.33 (2xpy-CH, 2H, d, J = 1.8 Hz),

SUBSTITUTE SHEET

7.65 (5-aromatic-CH, 1H, tr, $J = 7.5$ Hz), 8.08 (4,6-aromatic-CH, 2H, d,d, $J_1 = 7.5$ Hz, $J_2 = 2$ Hz), 8.47 (2-aromatic-CH, 1H, br, tr, $J = 2$ Hz); MS (FAB), 1037 ($-2 \times \text{Cl-H}$, 0.43).

5 EXAMPLE 19

Bis-distamycin (Compound 31)

A solution of benzene-1,2-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and
10 diisopropylethylamine (Hunig's base, 16 μL , 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μL , 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the
15 crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 83% yield. m.p., 245°C; $^1\text{H-NMR}$ (CD_3OD), 2.71 [$2 \times \text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J = 6$ Hz], 3.63 ($2 \times \text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 3.87 ($2 \times \text{NCH}_3$, 6H, s), 3.88 ($2 \times \text{NCH}_3$, 6H, s),
20 3.90 ($2 \times \text{NCH}_3$, 6H, s), 6.89 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 6.91 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 6.97 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 7.15 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 7.18 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 7.24 ($2 \times \text{py-CH}$, 2H, d, $J = 2$ Hz), 7.60 ($2 \times \text{m-aromatic-CH}$, 2H, q, $J = 3$ Hz), 7.68 ($2 \times \text{o-aromatic-CH}$,
25 2H, q, $J = 3$ Hz); MS (FAB), 1037 ($\text{m-}2 \times \text{Cl-H}$, 0.65).

EXAMPLE 20

Bis-distamycin (Compound 32)

A solution of 3,5-pyridine dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added
30 to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μL , 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μL , 0.09 mmol) in 3 mL of THF was added to the reaction solution. The
35 resulting mixture was stirred overnight. The solvent was

evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid m.p. 250°C in 88% yield. m.p., 250°C; ¹H-NMR, 2.52 [2xCH₂C(NH₂)₂Cl, 4H, m], 3.48 (2xCONHCH₂, 4H, m), 3.81 (2xNCH₃, 6H, s), 3.85 (2xNCH₃, 6H, s), 3.88 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 6.96 (2xpy-CH, 2H, m), 7.09 (2xpy-CH, 2H, d, J = 2 Hz), 7.17 (py-CH, 1H, d, J = 2 Hz), 7.19 (2xpy-CH, 2H, d, J = 2 Hz), 7.25 (2xpy-CH, 2H, d, J = 2 Hz), 7.29 (py-CH, 1H, m), 7.40 (py-CH, 1H, m), 7.42 (py-CH, 1H, m), 8.23 (2xCONHCH₂, 2H, m), 8.25 (3-py-CH, 1H, d, J = 8 Hz), 8.54 (4-py-CH, 1H, m), 8.64 [2xC(NH₂)₂Cl, 4H, s], 8.99 [2xC(NH₂)₂Cl, 4H, s], 9.20 (96-py-CH, 1H, m), 9.95 (2xpy-NHCO, 2H, s), 10.04 (2xpy-NHCO, 2H, s), 10.94 (py-NHCO, 1H, s), 11.00 (py-NHCO, 1H, s); (CD₃OD), 2.72 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.65 (2xCONHCH₂, 4H, tr, J = 6 Hz), 3.87 (2xNCH₃, 6H, s), 3.91 (2xNCH₃, 6H, s), 3.94 (NCH₃, 3H, s), 3.954 (NCH₃, 3H, s), 6.90 (2xpy-CH, 2H, d, J = 2 Hz), 6.98 (2xpy-CH, 2H, d, J = 2 Hz), 7.07 (py-CH, 1H, d, J = 2 Hz), 7.10 (py-CH, 1H, d, J = 2 Hz), 7.15 (2xpy-CH, 2H, d, J = 2 Hz), 7.20 (2xpy-CH, 2H, d, J = 2 Hz), 7.34 (py-CH, 1H, d, J = 2 Hz), 7.41 (py-CH, 1H, d, J = 2 Hz), 8.27 (3-py-CH, 1H, d, J = 8 Hz), 8.44 (4-py-CH, 1H, m), 9.17 (6-py-CH, 1H, m); MS (FAB), 1038 (M-2xCl-H, 0.03).

25 EXAMPLE 21

Bis-distamycin (Compound 33)

A solution of pyridine-3,6-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μL, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μL, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a

light yellow solid in 74% yield. m.p., 260°C; ¹H-NMR, 2.62 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.50 (2xCONHCH₂, 4H, q, J = 6 Hz), 3.81 (2xNCH₃, 6H, s), 3.85 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 6.96 (2xpy-CH, 2H, d, J = 2 Hz), 7.08 (2xpy-CH, 2H, d, J = 2 Hz), 7.16 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.26 (2xpy-CH, 2H, d, J = 2 Hz), 7.39 (2xpy-CH, 2H, d, J = 2 Hz), 8.23 (2xCONHCH₂, 2H, tr, J = 6 Hz), 8.59 [2xC(NH₂)₂Cl, 4H, s], 8.87 (4-py-CH, 1H, br, s), 8.98 [2xC(NH₂)₂Cl, 4H, s], 9.24 (2,6-py-CH, 2H, d, J = 2 Hz), 9.94 (2xpy-NHCO, 2H, s), 10.05 (2xpy-NHCO, 2H, s), 10.83 (2xpy-NHCO, 2H, s); (CD₃OD), 2.71 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.64 (2xCONHCH₂, 4H, tr, J = 6 Hz), 3.87 (2xNCH₃, 6H, s), 3.99 (2xNCH₃, 6H, s), 4.02 (2xNCH₃, 6H, s), 6.88 (2xpy-CH, 2H, s), 6.96 (2xpy-CH, 2H, s), 7.07 (2xpy-CH, 2H, s), 7.15 (2xpy-CH, 2H, s), 7.19 (2xpy-CH, 2H, s), 7.35 (2xpy-CH, 2H, s), 8.82 (4-py-CH, 1H, s), 9.17 (2,5-py-CH, 2H, s); MS (FAB), (M-2xCL-H, 0.15).

EXAMPLE 22**20 Bis-distamycin (Compound 34)**

A solution of pyridine-2,6-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μL, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μL, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 54% yield. m.p., >260°C; ¹H-NMR, 2.62 [2xCH₂(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.50 (2xCONHCH₂, 4H, m), 3.82 (2xNCH₃, 6H, s), 3.86 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 6.97 (2xpy-CH, 2H, d, J = 2 Hz), 7.08 (2xpy-CH, 2H, d, J = 2 Hz), 7.15 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.25 (2xpy-CH, 2H,

SUBSTITUTE SHEET

d, $J = 2$ Hz), 7.39 (2xpy-CH, 2H, d, $J = 2$ Hz), 8.23 (2xCONHCH₂, 2H, tr, $J = 6$ Hz), 8.56 [2xC(NH₂)₂Cl, 4H, s], 8.85 (4-py-CH, 1H, tr, $J = 2$ Hz), 8.96 [2xC(NH₂)₂Cl, 4H, s], 9.24 (3,5-py-CH, 2H, d, $J = 2$ Hz), 9.94 (2xpy-NHCO, 2H, s), 10.04 (2xpy-NHCO, 2H, s), 10.81 (2xpy-NHCO, 2H, s); MS (FAB), 1038 (M-2xCl-H, 0.25).

EXAMPLE 23**Bis-distamycin (Compound 35)**

A solution of trans-1,2-cyclobutane-dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 78% yield. m.p., >230°C; ¹H-NMR, 2.05 (3,4-cyclobutane-CH₂, 4H, m), 2.60 (2xCH₂C(NH₂)₂Cl, 4H, tr, $J = 6$ Hz), 3.38 (1,2-cyclobutane-CH, 2H, m), 3.49 (2xCONHCH₂, 4H, tr, $J = 6$ Hz), 3.79 (2xNCH₃, 6H, s), 3.84 (2xNCH₃, 6H, s), 3.85 (2xNCH₃, 6H, s), 6.88 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 6.97 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 7.05 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 7.17 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 7.21 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 7.23 (2xpy-CH, 2H, d, $J = 1.8$ Hz), 8.22 (2xCONHCH₂, 2H, tr, $J = 6$ Hz), 8.55 [2xC(NH₂)₂Cl, 4H, s], 8.96 [2xC(NH₂)₂Cl, 4H, s], 9.88 (2xpy-NHCO, 2H, s), 9.94 (4xpy-NHCO, 2H, s); (CD₃OD), 2.20 (3,4-cyclobutane-CH₂, 4H, m), 2.71 (2xCH₂, 4H, tr, $J = 7$ Hz), 3.49 (1,2-cyclobutane-CH, 2H, m), 3.64 [2xCH₂C(NH₂)₂Cl, 4H, tr, $J = 7$ Hz), 3.87 (2xNCH₃, 6H, s), 3.89 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 6.84 (2xpy-CH, 2H, d, $J = 2$ Hz), 6.89

SUBSTITUTE SHEET

(2xpy-CH, 2H, d, J = 2 Hz), 6.95 (2xpy-CH, 2H, d, J = 2 Hz), 7.15 (2xpy-CH, 2H, d, J = 2 Hz), 7.18 (2xpy-CH, 2H, d, J = 2 Hz), 7.20 (2xpy-CH, 2H, d, J = 2 Hz); MS (FAB), 1015 (M-2xCl-H, 1.06).

5 EXAMPLE 24

Bis-distamycin (Compound 36)

A solution of maleic-dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and dissiopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 33% yield. m.p., >255°C; 1 H-NMR, 2.61 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.50 (2xCONHCH₂, 4H, q, J = 6 Hz), 3.82 (2xNCH₃, 6H, s), 3.85 (2xNCH₃, 6H, s), 3.87 (2xNCH₃, 6H, s), 6.97 (2xpy-CH, 2H, tr, J = 2 Hz), 7.07 (2xpy-CH, 2H, d, J = 2 Hz), 7.10 (-CH=CH-, 2H, s), 7.18 (2xpy-CH, 2H, s), 7.24 (2xpy-CH, 2H, d, J = 2 Hz), 7.35 (2xpy-CH, 2H, d, J = 2 Hz), 8.23 (2xCONHCH₂, 2H, tr, J = 6 Hz), 8.66 [2xC(NH₂)₂Cl, 4H, s], 8.94 [2xC(NH₂)₂Cl, 4H, s], 9.93 (2xpyNHCO, 2H, s), 9.99 (2xpy-NHCO, 2H, s), 10.54 (2xpy-NHCO, 2H, s), (CD₃OD), 2.72 [2xCH₂C(NH₂)₂Cl, 4H, tr, J = 6 Hz], 3.65 (2xCONHCH₂, 4H, tr, J = 6 Hz), 3.88 (2xNCH₃, 6H, s), 3.90 (2xNCH₃, 6H, s), 3.92 (2xNCH₃, 6H, s), 6.91 (2xpy-CH, 2H, tr, J = 2 Hz), 6.98 (2xpy-CH, 2H, d, J = 2 Hz), 7.09 (-CH=CH-, 2H, s), 7.16 (2xpy-CH, 2H, d, J = 2 Hz), 7.19 (2xpy-CH, 2H, d, J = 2 Hz), 7.33 (2xpy-CH, 2H, d, J = 2 Hz); MS (FAB), 987 (M-2xCl-H, 0.27).

EXAMPLE 25**Bis-distamycin (Compound 37)**

A solution of fumaroyl-dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent evaporated and the crude product was obtained as a light yellow solid in 67% yield. m.p., >280°C; $^1\text{H-NMR}$, 2.61 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J = 6$ Hz], 3.48 ($2\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz); 3.80 ($2\times\text{NCH}_3$, 6H, s), 3.84 ($2\times\text{NCH}_3$, 6H, s), 3.86 ($2\times\text{NCH}_3$, 6H, s), 6.35 ($-\text{CH}=\text{CH}-$, 2H, s), 6.84-7.84 ($12\times\text{py-CH}$, 12H, m), 8.24 ($2\times\text{CONHCH}_2$, 2H, tr, $J = 6$ Hz), 8.58-9.50 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 8H, br, s], 9.93 ($2\times\text{py-NHCO}$, 2H, s), 9.97 ($2\times\text{py-NHCO}$, 2H, s), 9.98 ($2\times\text{py-NHCO}$, 2H, s); (CD_3OD), 2.66 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, tr, $J = 6$ Hz], 3.58 ($2\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 3.79 ($2\times\text{NCH}_3$, 6H, s), 3.82 ($2\times\text{NCH}_3$, 6H, s), 3.84 ($2\times\text{NCH}_3$, 6H, s), 6.26 ($-\text{CH}=\text{CH}-$, 2H, s), 6.83 ($2\times\text{py-CH}$, 2H, d, $J = 2$ Hz), 6.87 ($2\times\text{py-CH}$, 2H, d, $J = 2$ Hz), 6.91 ($2\times\text{py-CH}$, d, $J = 2$ Hz), 7.13 ($2\times\text{py-CH}$, 2H, d, $J = 2$ Hz), 7.17 ($2\times\text{py-CH}$, 2H, d, $J = 2$ Hz), 7.27 ($2\times\text{py-CH}$, 2H, d, $J = 2$ Hz); MS (FAB), no $M+1$ peak.

EXAMPLE 26**Bis-distamycin 35 (Compound 38)**

A solution of trans-5,6-bicyclo[2,2,1]-hept-2-ene dicarbonyl dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of deformyl distamycin (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the

crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 53% yield. m.p., 260°C; ^1H -NMR, 1.31 (7-bicyclohept, 1H, s), 1.86 (7-bicyclohept, 1H, d, $J = 7$ Hz), 2.76 (5-endo-bicyclohept, 1H, d, $J = 8$ Hz), 2.93 (4-bicyclohept, 1H, s), 3.35 (1-bicyclohept, 1H, s), 3.50 (6-exo-cyclohept, 1H, s), 3.50 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, m], 3.81 ($3\times\text{NCH}_3$, 9H, s), 3.85 ($3\times\text{NCH}_3$, 9H, s), 5.98 (3-bicyclohept, 1H, d,d, $J = 2.5$ Hz), 6.30 (2-bicyclohept, 1H, d,d, $J = 2.5$ Hz), 6.86 (py-CH, 1H, d, $J = 2$ Hz), 6.91 (py-CH, 1H, d, $J = 2$ Hz), 6.97 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.06 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.13 (py-CH, 1H, d, $J = 2$ Hz), 7.18 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.19 (py-CH, 1H, d, $J = 2$ Hz), 7.23 (2xpy-CH, 2H, tr, $J = 2$ Hz), 8.24 ($2\times\text{CONHCH}_2$, 2H, m), 8.57 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, m] 8.97 [$2\times\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, m], 9.88 (py-NHCO, 1H, m), 9.92 (4xpy-CH, 4H, m), 10.11 (1py-NHCO, 1H, m); (CD_3OD), 1.47 (7-bicyclohept, 1H, d, $J = 8$ Hz), 1.94 (7-bicyclohept, 1H, d, $J = 8$ Hz), 2.71 [$2\times\text{CH}_2\text{C}(\text{NH}_2)_2\text{Cl}$, 4H, d, $J = 6$ Hz], 2.77 (5-endo-bicyclohept, 1H, d, $J = 4$ Hz), 3.04 (4-bicyclohept, 1H, s), 3.47 (6-exo-bicyclohept, 1H, s), 3.64 ($2\times\text{CONHCH}_2$, 4H, tr, $J = 6$ Hz), 3.87 ($2\times\text{NCH}_3$, 9H, s), 3.89 (NCH_3 , 3H, s), 3.90 ($2\times\text{NCH}_3$, 6H, s), 6.08 (3-bicyclohept, 1H, d, $J = 2.5$ Hz), 6.37 (2-bicyclohept, 1H, d, $J = 2.5$ Hz), 6.82 (py-CH, 1H, d, $J = 2$ Hz), 6.83 (py-CH, 1H, d, $J = 2$ Hz), 6.89 (2xpy-CH, 2H, d, $J = 2$ Hz), 6.95 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.11 (py-CH, 1H, d, $J = 2$ Hz), 7.14 (2xpy-CH, 2H, d, $J = 2$ Hz), 7.17 (3xpy-CH, 3H, tr, $J = 2$ Hz); MS (FAB), 1053 ($\text{M}-2\times\text{Cl}-\text{H}$, 0.21).

SUBSTITUTE SHEET

EXAMPLE 27**Bis-Lexitropsin (Compound 39)**

A solution of maleic-dichloride (9.28 mg, 0.046 mmol) in 5 mL of tetrahydrofuran was added to a solution of 3-[1-methyl-4-(4-amino-1-methylimidazole-2-carboxamido)imidazole-2-carboxamido]propionamidinium hydrochloride (48 mg, 0.09 mmol) and diisopropylethylamine (Hunig's base, 16 μ L, 0.09 mmol) in 3 mL of dimethylformamide cooled to 0°C. After 10 min, a solution of Hunig's base (16 μ L, 0.09 mmol) in 3 mL of THF was added to the reaction solution. The resulting mixture was stirred overnight. The solvent was evaporated and the crude product was recrystallized from methanol and ether. The final product was obtained as a light yellow solid in 73% yield. m.p., >250°C; $^1\text{H-NMR}$, 1.86 (2xCH₂CH₂CH₂, 4H, q, J = 8 Hz), 3.00 [2xCH₂N(CH₃)₂, 4H, tr, J = 8 Hz], 3.30 (2xCONHCH₂, 4H, m), 3.96 (2xNCH₃, 6H, s), 4.02 (2xNCH₃, 6H, s), 7.28 (-CH=CH-, 2H, s), 7.54 (2xim-CH, 2H, s), 7.67 (2xim-CH, 2H, s), 8.52 (2xCONHCH₂, 2H, tr, J = 6 Hz), 9.43 (2xpy-NHCO, 2H, s), 11.01 (2xpy-NHCO, 2H, s); MS (FAB), 777 (M-2xCl-H, 3.11).

Other compounds shown in Table I were similarly prepared and their analytical and physical data are summarized therein.

EXAMPLE 28

Drug-DNA binding constants of the compounds of the present invention were estimated. To 2 mL of Tris-EDTA buffer, pH 8, containing 1.3 μ M ethidium bromide, calf thymus DNA was added to give a final concentration of 1.35 μ M. The fluorescence was measured after equilibration for a few minutes, using a Turner model 430 spectrofluorometer (Turner Amsco Instruments, Carpinteria, CA) equipped with a 150 W xenon lamp, at an excitation wavelength of 525 nm and an emission wavelength of 600 nm. Aliquots of concentrated drug solutions were added and the

SUBSTITUTE SHEET

fluorescence measured. Controls were performed to show that the drugs themselves did not interfere with the fluorescence measurements at the levels employed. From a plot of the decreased fluorescence of the ethidium-DNA complex with increase dose of drug, the concentration of drug needed to reduce the fluorescence by 50% was determined and used to calculate a relative binding constant for the drug, given the binding constant of ethidium to be 10^7 M^{-1} under similar conditions.

10 The results of binding tests are shown in Table II and in Table III.

EXAMPLE 29

15 Compounds of the present invention were tested for anti-Moloney murine leukemia virus (MLV). The method utilized was adapted from Rowe et al (1970) and Lin et al (1987).

 The following materials were utilized in the method:

- 20 - Retroviruses; rauscher - ATCC 998
 moloney LT(V) - ATCC 190
 Leukosis-sarcoma complex - ATCC 245
- cells; SC-1 - ATCC CRL 1404
 XC - ATCC CCL 165
- 25 - minimum essential medium (eagle) with Hanks Bss, supplemented with 10% fetal bovine serum, 100 IU ml^{-1} penicillin G, 100 ugml^{-1} streptomycin, 2.5 ugml^{-1} amphotericin B and non-essential amino acids (Sigma M2025).
- 30 - Dulbecco's modified eagles medium, supplemented with 10% fetal bovine with 5% fetal bovine serum, 100 ugml^{-1} penicillin G, 100 ugml^{-1} streptomycin and 2.5 ugml^{-1} amphotericin B.
- 35 - minimum essential medium (eagle) with earles salt supplemented with 5% fetal bovine serum, 100 ugml^{-1} penicillin G, 100 ugml^{-1} streptomycin and non-essential aminoacids (Sigma M2025).

- phosphate buffered saline.
- crystal violet dye.
- 24 well plates.

5 - compounds dissolved in DMSO (or water) to 2-20 μgml^{-1} then further diluted in 5% FBS-MEM.

10 Stock cell cultures were prepared in the 10% FBS-Dulbecco. To prepare 24 well plates for experiments, 0.8ml of 3.5×10^4 SC1 cells ml^{-1} were added to each well one day in advance. This was using the 5% FBS-MEM. 0.1 ml of each compound dilution, in triplicate, was added to a well in the plate. 0.1 ml of 20-40 p.f.u. of moloney virus was added to each well of the plate. Those plates were shaken on a mechanical shaker at 0, 30 and 60 minutes. They were incubated for 5 days at 37°C in a 5% CO_2 incubator. The medium was removed and plates were subjected to ultraviolet light (175 W cm^2 at surface) for three minutes.

20 0.8 ml of 2×10^5 XC cells ml^{-1} were added to each well using the 10% FBS-Hanks mem. The plates were incubated at 37°C, 5% CO_2 for 4 days, but the medium was replaced after 2 days. The medium was removed, the wells were washed with pbs and 0.25 ml of 0.05% crystal violet was added to each well for 2 hours. The plates were washed, dried and the plaques counted.

25 MIC_{50} values were calculated using the formula -
 $\frac{\% \text{ inhibition greater than } 50\% - 50\%}{\% \text{ inhibition greater than } 50\% - \% \text{ inhibition less than } 50\%}$
 to give the interpolative values between two dilutions.

30 The results of the test are shown in Tables IV and V and demonstrate comparative anti-MLV activity between compounds of the present invention and AZT and DDC.

SUBSTITUTE SHEET

EXAMPLE 30

- Compounds of the present invention were tested for anti-HIV activity by the National Cancer Institute (NIH, Bethesda). The procedure used by the National Cancer Institute is described in Weislow, O.W. et al, J. Natl. Cancer Inst., Vol. 81, pages 577-586 (1989). NCI uses this procedure to test for agents active against Human Immunodeficiency Virus (HIV) and is designed to detect agents acting at any stage of the virus reproductive cycle. The assay basically involves the killing of T4 lymphocytes by HIV. Small amounts of HIV are added to cells, and a complete cycle of virus reproduction is necessary to obtain the required cell killing. Agents that interact with virions, cells, or virus gene-products to interfere with viral activities will protect cells from cytolysis. The system is automated in several features to accommodate large numbers of candidate agents and is generally designed to detect anti-HIV activity. However, compounds that degenerate or are rapidly metabolized in the culture conditions may not show activity in this screen. All tests are compared with at least one positive (e.g., AZT-treated) control done at the same time under identical conditions. The procedure is set forth below:
1. Candidate agent is dissolved in dimethyl sulfoxide (unless otherwise instructed) then diluted 1:100 in cell culture medium before preparing serial half-log₁₀ dilutions. T4 lymphocytes (CEM cell line) are added and after a brief interval HIV-1 is added, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compound serve as a toxicity control, and infected and uninfected cells without the compound serve as basic controls.
 2. Cultures are incubated at 37° in a 5% carbon dioxide atmosphere for 6 days.

3. The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells.
- 5 4. Individual wells are analyzed spectrophotometrically to quantitate formazan production, and in addition are viewed microscopically for detection of viable cells and confirmation of protective activity.
- 10 5. Drug-treated virus-infected cells are compared with drug-tested noninfected cells and with other appropriate controls (untreated infected and untreated noninfected cells, drug-containing wells without cells, etc.) on the same plate.
- 15 6. Data are reviewed in comparison with other tests done at the same time and a determination about activity is made.

The test results for five of the active compounds are set forth in the Figures 2-6 and the corresponding Tables VI-X below and test results of the compounds of the present invention are compiled in Table XI.

SUBSTITUTE SHEET

Table I. Analytical and physical data on linked netropsins and their precursors

	Comp.	Yield(5)	m.p. ^a	Formula	Analysis
5	15	85	210°	C ₄₆ H ₅₈ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	16	76	210°	C ₅₀ H ₆₀ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	17	84	198-202	C ₅₂ H ₆₄ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	18	69	215	C ₆₆ H ₉₂ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	19a	99	305-6°	C ₃₈ H ₃₈ N ₁₂ O ₆	C, H, N
10	19b	64	262-8°	C ₃₈ H ₄₆ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	20a	95	278-82°	C ₃₈ H ₃₈ N ₁₂ O ₆	C, H, N,
	20b	78	248-50°	C ₃₈ H ₄₆ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	21a	84.7	289-90°	C ₃₄ H ₃₆ N ₁₂ O ₆	C, H, N
	21b	58	295°	C ₃₄ H ₄₄ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
15	22a	56.5	250-2°	C ₃₄ H ₃₆ N ₁₂ O ₆	C, H, N,
	22b	85	217°	C ₃₄ H ₄₄ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	23a	88.6	312° (dec)	C ₃₅ H ₃₈ N ₁₂ O ₆	C, H, N
	23b	68.5	210° (softens)	C ₃₅ H ₄₆ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	24a	59	175°	C ₃₅ H ₃₈ N ₁₂ O ₆	C, H, N
20	24b	70.6	204° (softens)	C ₃₅ H ₄₆ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	25a	69	172° (softens)	C ₃₆ H ₄₀ N ₁₂ O ₆	C, H, N,
	25b	77	238° (softens)	C ₃₆ H ₄₈ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	26a	70	165-8°	C ₃₇ H ₄₂ N ₁₂ O ₆	C, H, N,
	26b	46	231°	C ₃₇ H ₅₀ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
25	27a	82.6	189°	C ₃₈ H ₄₄ N ₁₂ O ₆	C, H, N
	27b	61	201° (softens)	C ₃₈ H ₅₂ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	28a	54	175°	C ₃₈ H ₄₄ N ₁₂ O ₆	C, H, N
	28b	23	198°	C ₃₈ H ₅₂ N ₁₄ O ₆ Cl ₂	C, H, N, Cl
	29	77	>300	C ₅₀ H ₅₈ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
30	30	68	240	C ₅₀ H ₅₈ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	31	83	245	C ₅₀ H ₅₈ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	32	88	250	C ₄₉ H ₅₇ N ₁₉ O ₈ Cl ₂	C, H, N, Cl
	33	74	260	C ₄₉ H ₅₇ N ₁₉ O ₈ Cl ₂	C, H, N, Cl
	34	54	260	C ₄₉ H ₅₇ N ₁₉ O ₈ Cl ₂	C, H, N, Cl
35	35	78	230	C ₄₈ H ₆₀ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	36	33	255	C ₄₆ H ₅₆ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	37	67	280	C ₄₆ H ₅₆ N ₁₈ O ₈ Cl ₂	C, H, N, Cl
	38	53	260	C ₅₁ H ₆₂ N ₁₈ O ₈ Cl ₃	C, H, N, Cl
	39	73	250	C ₃₄ H ₅₀ N ₁₆ O ₆ Cl ₂	C, H, N, Cl

40 a. Uncorrected.

b. All compounds gave satisfactory elemental analyses within 0.4% of the calculated values and exhibited ¹H-NMR, IR and MS data consistent with the structures.

TABLE II. Relative binding constants for natural and linked oligopeptides $R_1CO(CH_2)_nCO-R_1$ to calf thymus DNA determined by ethidium displacement assay.^a

Compound	n^b	DNA Binding Constant (M^{-1})
1	--	1.9×10^7
2	--	0.8×10^7
3	0	5.6×10^7
4	1	3.6×10^7
5	2	7.2×10^7
8	5	1.2×10^7
9	6	2.5×10^7
10	7	0.9×10^7
11	8	1.7×10^7
12	9	1.9×10^7
13	10	2.2×10^7

^aBased on a binding constant of ethidium of $10^7 M^{-1}$ under similar conditions of temperature, pH and ionic strength. Binding constant values represent the average of repeat measurements.

^bNumber of CH_2 units in the linker in $R_1-CO(CH_2)_nCO-R_1$.

TABLE III. Relative binding constants for cis and trans bis-netropsins to poly(dA-dT) determined by the ethidium displacement assay.^a

Compound	$K_{app}(M^{-1})$
1	9.4×10^7
2	6.3×10^7
19b	4.3×10^7
20b	4.9×10^7
21b	4.9×10^7
22b	3.8×10^7
23b	5.3×10^7
24b	4.4×10^7
25b	5.6×10^7
26b	3.1×10^7
27b	4.0×10^7

^aBased on a binding constant of ethidium of $9.5 \times 10^6 M^{-1}$ under similar conditions of temperature, pH and ionic strength. Binding constants represent the average of repeat measurements.

SUBSTITUTE SHEET

TABLE IV.

	Compound	Toxicity, TD_{50} ($\mu\text{g mL}^{-1}$)	Activity, MIC_{50} ($\mu\text{g mL}^{-1}$)	T.I., $TD_{50}/$ MIC_{50}
5	29	>100.00	3.98	>25.13
	30	>100.00	>50.0	2.0
	31	>100.00	79.63	>1.26
	32	>100.00	15.93	>6.28
10	33	>100.00	>100.00	--
	34	>100.00	22.74	>4.40
	35	83.50	>50.0	1.7
	36	100.00	0.16	625.00
	37	84.29	11.21	7.52
15	38	>100.00	22.04	>4.54
	39	>100.00	>100.00	--
	AZT	>100.00	0.0014	>7.14x10 ⁵
	DDC	>100.00	0.74	>135.14

20 TABLE V. Inhibition of Moloney murine leukemia (MLV) associated reverse transcriptase activity by linked.

	Compound	n ^a	ID_{50}^b ($\mu\text{g/mL}$) (average \pm SD)
25	4	1	39.0 \pm 13.9
	4	2	25.2 \pm 11.4
	8	5	72.5 \pm 7.69
	9	6	21.3 \pm 6.1
	10	7	34.2 \pm 0.9
	11	8	20.3 \pm 9.2
30	12	9	10.3 \pm 7.5
	13	10	9.1 \pm 6.7
	23b	--	7.0 \pm 3.6
	24b	--	30.4 \pm 19.3
	25b	--	21.8 \pm 9.2
35	26b	--	45.9 \pm 11.3
	27b	--	29.1 \pm 6.0
	28b	--	63.8 \pm 41.0
	Aurintricarboxylic acid		1.42 \pm 0.26

^aNumber of CH₂ groups in linker in R₁-CO(CH₂)_nCO-R₁.

40 ^b50% inhibitory dose, measured after 120 min incubation of the reaction mixtures. [MLV: lot 804-845-8A; (³H-methyl)dTTP at 10 μ C; (specific activity: 30 Curies/mmol) per 250 μ L of reaction mixture.]

SUBSTITUTE SHEET

TABLE VI

Results of the compound N,N'-di[1-methyl-2-[1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] terephthalamide dihydrochloride.

SUMMARY		DOSE	INFECTED RESPONSE	UNINFECTED RESPONSE
Index	Concentration	(Molar)	% of Control	% of Control
IC50 (Molar)	$>1.79 \times 10^{-5}$	5.68×10^{-9}	39.64	88.62
EC50 (Molar)	2.08×10^{-6}	1.79×10^{-8}	33.00	92.56
TI50 (IC/EC)	$>8.59 \times 10^0$	5.68×10^{-8}	25.70	94.69
		1.79×10^{-7}	29.97	92.72
		5.67×10^{-7}	28.86	88.21
		1.79×10^{-6}	51.73	136.50
		5.66×10^{-6}	134.54	164.46
		1.79×10^{-5}	167.25	192.17

5

TABLE VII

Results of the compound N,N'-di[1-methyl-2-[1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] isophthalamide dihydrochloride.

SUMMARY		DOSE	INFECTED RESPONSE	UNINFECTED RESPONSE
Index	Concentration	(Molar)	% of Control	% of Control
IC50 (Molar)	2.84×10^{-4}	4.28×10^{-7}	48.47	116.38
EC50 (Molar)	3.55×10^{-6}	1.35×10^{-6}	29.25	131.95
TI50 (IC/EC)	$8.00 \times 10^{+1}$	4.27×10^{-6}	64.76	123.64
		1.35×10^{-5}	117.45	117.76
		4.26×10^{-5}	120.68	123.27
		1.34×10^{-4}	63.57	142.80
		4.26×10^{-4}	0.02	-0.29
		1.34×10^{-3}	4.26	10.39

TABLE VIII

Results of the compound N,N'-di[1-methyl-2-[1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole]-4-4pyrrolyl] fumaride dihydrochloride.

SUMMARY		DOSE	INFECTED RESPONSE	UNINFECTED RESPONSE
Index	Concentration	(Molar)	% of Control	% of Control
IC50 (Molar)	$>3.30 \times 10^{-5}$	1.05×10^{-8}	18.00	83.05
EC50 (Molar)	1.67×10^{-6}	3.32×10^{-8}	22.96	87.56
TI50 (IC/EC)	$>1.97 \times 10^{+1}$	1.05×10^{-7}	26.15	90.26
		3.31×10^{-7}	28.00	88.21
		1.04×10^{-6}	38.90	83.87
		3.31×10^{-6}	96.78	151.83
		1.04×10^{-5}	150.24	154.79
		3.30×10^{-5}	132.20	138.63

5

TABLE IX

Results of the compound N,N'-di[1-methyl-2-[1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole]-4-pyrrolyl]maleamide dihydrochloride.

SUMMARY		DOSE	INFECTED RESPONSE	UNINFECTED RESPONSE
Index	Concentration	(Molar)	% of Control	% of Control
IC50 (Molar)	1.63×10^{-4}	3.04×10^{-7}	28.75	100.16
EC50 (Molar)	4.04×10^{-6}	9.61×10^{-7}	32.14	100.02
TI50 (IC/EC)	$4.04 \times 10^{+1}$	3.03×10^{-6}	44.03	103.19
		9.59×10^{-6}	115.19	112.20
		3.03×10^{-5}	114.32	112.05
		9.58×10^{-5}	84.02	94.18
		3.02×10^{-4}	-0.29	-0.86
		9.57×10^{-4}	-0.14	5.40

TABLE X

Results of the compound N,N'-di[1-methyl-2-[1-methyl-2-carboxamido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] trans 1,2-cyclobutaneamide dihydrochloride.

SUMMARY		DOSE	INFECTED RESPONSE	UNINFECTED RESPONSE
Index	Concentration	(Molar)	% of Control	% of Control
IC50 (Molar)	1.67×10^{-4}	2.94×10^{-7}	42.92	90.95
EC50 (Molar)	1.39×10^{-6}	9.29×10^{-7}	59.07	102.41
TI50 (IC/EC)	$1.20 \times 10^{+2}$	2.93×10^{-6}	77.00	116.36
		9.28×10^{-6}	80.26	145.18
		2.93×10^{-5}	110.05	174.62
		9.27×10^{-5}	90.52	101.95
		2.92×10^{-4}	0.04	0.54
		9.25×10^{-4}	9.72	8.29

5 TABLE XI

The following Table XI shows the results of anti-HIV-1 data on the oligopeptides of the present invention and their anti-HIV-1 activity is designated as inactive, moderate or active. Compounds 19b, 20b, 21b, 25b, 29, 30, 32, 34 and 36 are designated as active.

10

TABLE XI Anti-HIV-1 Activity


	<u>Compound</u>	<u>IC₅₀(μM)</u>	<u>EC₅₀</u>	<u>TI₅₀</u>	<u>Activity*</u>
5	3	83.5	11.9	7.01	Moderate
	5	75.3	12	6.3	Moderate
	8	64.8	5.3	12.1	Moderate
	9	--	--	--	Inactive
	10	51.1	2.1	24.1	Moderate
10	11	--	--	--	Inactive
	12	57	3.9	1.46	Moderate
	13	78	6.6	11.7	Moderate
	15	41	41	1.0	Inactive
	16	>100	--	--	Inactive
15	17	29	14	2	Moderate
	18	>120	--	--	Inactive
	19b	17.9	1.21	14.8	Active
	20b	284	3.55	80	Active
	21b	33	1.37	24.1	Active
20	22b	199	0.35	566	Active
	23b	9.3	3.44	2.7	Moderate
	24b	257	42.5	6.1	Moderate
	25b	68.2	0.42	161	Active
	26b	168	46.3	3.6	Moderate
25	27b	181	5.6	32.4	Moderate
	29	4.7	0.39	12	Active
	30	140	21	6.6	Active
	32	69	1.6	43	Active
	33	69	9.8	7.0	Moderate
30	34	140	13	11	Active
	35	71	16	4.5	Moderate
	36	207	10.4	19.8	Active
	37	35	--	--	Inactive

* National Cancer Institute Designation

SUBSTITUTE SHEET

IN THE CLAIMS:

1. A method for treating a patient infected with a retrovirus, comprising administering to the patient an antiretroviral effective amount of a compound of the formula:



wherein:

A is a moiety bearing a positive charge and of a size which does not inhibit binding of said compound to nucleic acid sequences associated with the cellular action of retroviruses;

R₁ is a moiety derived from a residue of carbonic acid or a residue of a dicarboxylic acid selected from the group consisting of:

(i) a residue of a dicarboxylic acid of the formula -CO-C_p-H_{2p}-CO where p equals 1 to 22;

(ii) a residue of an unsaturated aliphatic dicarboxylic acid of the formula -CO-C_q-H_{2q-2}-CO- where q equals 2 to 22;

(iii) a residue of an aromatic dicarboxylic acid;

(iv) a residue of a cycloalkane dicarboxylic acid of the formula -CO-C_r-H_{2r-2}-CO- where r equals 3 to 7, optionally fused to one or more three to seven membered C rings; and

(v) a residue of a cycloalkene dicarboxylic acid of the formula -CO-C_s-H_{2s-4}-CO where s equals 3 to 7;

Het is a five membered heterocyclic moiety selected from the group consisting of a pyrrole, an imidazole, a triazole, a pyrazole, a thiazole, a thiophene, a furan and an oxazole;

x is 0 or 1;

y is 0, 1, 2 or 3;

z is 0, 1, 2 or 3;

SUBSTITUTE SHEET

R_2 , R_3 , R_4 and R_5 are attached to a ring atom other than carbon and are independently selected from the group consisting of C_1 - C_6 alkyl and $-CH_2-O-R_6$, where R_6 is a C_1 - C_6 alkyl;

5 and salts thereof.

2. The method of claim 1, wherein A is a moiety selected from the group consisting of an amidine, a guanidine, secondary ammonium salts, tertiary ammonium salts, quaternary ammonium salts, sulfonium salts and phosphonium salts.

10

3. The method of claim 1, wherein R_2 , R_3 , R_4 and R_5 are each a C_1 - C_6 alkyl.

4. The method of claim 1, wherein R_2 , R_3 , R_4 and R_5 are the same and are a C_1 - C_6 alkyl group.

15 5. The method of claim 1, wherein R_2 , R_3 , R_4 and R_5 are each a methoxymethyl.

6. The method of claim 1, wherein R_1 is



20 7. The method of claim 1, wherein R_1 is a residue of a dicarboxylic acid of the formula $-CO-C_pH_{2p}-CO-$ where p equals 1 to 22.

8. The method of claim 1, wherein R_1 is a residue of a dicarboxylic acid selected from the group consisting of:
 25 a residue of an unsaturated aliphatic dicarboxylic acid of the formula $-CO-C_q-H_{2q-2}-CO-$ where q equals 2; a residue of an aromatic dicarboxylic acid; and a residue of a cycloalkane dicarboxylic acid of the formula $-CO-C_r-H_{2r-2}-CO-$ where r equals 3 to 6.

9. The method of claim 1, wherein the compound is *N,N'*-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] terephthalamide dihydrochloride.


5 10. The method of claim 1, wherein the compound is *N,N'*-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] isophthalamide dihydrochloride.

10 11. The method of claim 1, wherein the compound is *N,N'*-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] fumaramide dihydrochloride.

15 12. The method of claim 1, wherein the compound is *N,N'*-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] maleamide dihydrochloride.


20 13. The method of claim 1, wherein the compound is *N,N'*-di[1-methyl-2-[1-methyl-2-carboximido(3-propionamidine)-4-pyrrole]-4-pyrrolyl] trans 1,2-cyclobutanamide dihydrochloride.

14. The method of claim 1, wherein the compound is:




SUBSTITUTE SHEET


and R is




15. The method of claim 1, wherein the compound is:




and R is




16. The method of claim 1, wherein the compound is:



and R is




17. The method of claim 1, wherein the compound is:




62/1


and R is



18. The method of claim 1, wherein the compound is:



and R is




62/2

19. The method of claim 1, wherein said retrovirus is Human Immunodeficiency Virus.

20. The method of claim 1, wherein the antiretroviral effective dose is in a range of 1 to 200 mg/kg body weight per day.

21. The method of claim 1, wherein the compound is administered intravenously or orally.


22. A compound exhibiting activity against retroviruses, represented by the formula:




wherein R_1 is a moiety derived from a residue of a dicarboxylic acid selected from the group consisting of:
 a residue of a C_6 aromatic dicarboxylic acid; a residue of

an unsaturated aliphatic dicarboxylic acid of the formula
 $\text{CO}-\text{C}_q-\text{H}_{2q-2}-\text{CO}-$ where q equals 2; a residue of a
 cycloalkane dicarboxylic acid of the formula
 $\text{CO}-\text{C}_r-\text{H}_{2r-2}-\text{CO}$ where r equals 3 to 6 optionally fused to
 one or more three to seven C membered rings, and A , R_2 ,
 5 R_3 , R_4 , R_5 and x , y and z are as defined in claim 1;
 and salts thereof.

23. The compound of claim 22, wherein R_1 is



24. The compound of claim 22, wherein R_1 is




25. The compound of claim 22, wherein R_1 is a
 dicarboxylic acid residue of cyclopropane.


26. The compound of claim 22, wherein R_1 is a
 dicarboxylic acid residue of cyclopentane.

20 27. The compound of claim 22, wherein R_1 is a
 dicarboxylic acid residue of cyclohexane.


28. The compound of claim 22, wherein R_1 is



29. The compound of claim 22, wherein R_1 is



30. A pharmaceutical composition suitable for the treatment of retroviral infections, comprising a compound of the formula:



wherein:

A is a moiety bearing a positive charge and of a size which does not inhibit binding of said compound to nucleic acid sequences associated with the cellular action of retroviruses;

R₁ is a moiety derived from a residue of carbonic acid or a residue of a dicarboxylic acid selected from the group consisting of:

(i) a residue of a dicarboxylic acid of the formula -CO-C_p-H_{2p}-CO where p equals 1 to 16;

(ii) a residue of an unsaturated aliphatic dicarboxylic acid of the formula -CO-C_q-H_{2q-2}-CO- where q equals 2 to 16;

(iii) a residue of an aromatic dicarboxylic acid;

(iv) a residue of a cycloalkane dicarboxylic acid of the formula -CO-C_r-H_{2r-2}-CO- where r equals 3 to 7 optionally fused to one or more three to six C membered rings; and

(v) a residue of a cycloalkene dicarboxylic acid of the formula -CO-C_s-H_{2s-4}-CO where s equals 3 to 7;

Het is a five membered heterocyclic moiety selected from the group consisting of a pyrrole, an imidazole, a triazole, a pyrazole, a thiazole, a thiophene, a furan and an oxazole;

x is 0 or 1;


y is 0, 1, 2 or 3;

z is 0, 1, 2 or 3;

R₂, R₃, R₄ and R₅ are attached to a ring atom other than carbon and are independently selected from the group

consisting of C₁-C₆ alkyl and -CH₂-O-R₆ is a C₁-C₆ alkyl;
and salts thereof, in a pharmaceutically acceptable
carrier.

31. A process for the preparation of a compound of
the formula:



wherein:

A is a moiety bearing a positive charge and of a size
which does not inhibit binding of said compound to nucleic
acid sequences associated with the cellular action of
retroviruses;

R₁ is a moiety derived from a residue of carbonic
acid or a residue of a dicarboxylic acid selected from the
group consisting of:

- (i) a residue of a dicarboxylic acid of the formula
-CO-C_p-H_{2p}-CO where p equals 1 to 16;
- (ii) a residue of an unsaturated aliphatic
dicarboxylic acid of the formula -CO-C_q-H_{2q-2}-CO- where q
equals 2 to 16;

- (iii) a residue of an aromatic dicarboxylic acid;
- (iv) a residue of a cycloalkane dicarboxylic acid of
the formula -CO-C_r-H_{2r-2}-CO- where r equals 3 to 7
optionally fused to a three to seven C membered ring; and
- (v) a residue of a cycloalkene dicarboxylic acid of
the formula -CO-C_s-H_{2s-4}-CO where s equals 3 to 7;

Het is a five membered heterocyclic moiety selected
from the group consisting of a pyrrole, an imidazole, a
triazole, a pyrazole, a thiazole, a thiophene, a furan and
an oxazole;

x is 0 or 1;


y is 0, 1, 2 or 3;

66

z is 0, 1, 2 or 3;


R₂, R₃, R₄ and R₅ are attached to a ring atom other than carbon and are independently selected from the group consisting of C₁-C₆ alkyl and -CH₂-O-R₆ is a C₁-C₆ alkyl;

5 and salts thereof, comprising the steps of:
reacting a compound of the formula (II)



with a dicarboxylic acid of the formula (III)

10



(III)

and converting B to A to form said moiety bearing a positive charge,

wherein;

15

x, y and R₁ are as defined above;

B is the same as A or is a group with a nitrile, halogen or sulfide substituent; and

X is a halogen, imidazolidine or other reactive moiety.

SUBSTITUTE SHEET

1/6




Fig.1

2 / 6




Fig.2

SUBSTITUTE SHEET

3 / 6




Fig.3

4 / 6




Fig.4

SUBSTITUTE SHEET

5 / 6




Fig.5

6 / 6




Fig.6

International Application No PCT/CA 92/00051

International Application No PCT/CA 92/00051

According to International Patent Classification (IPC) or to both National Classification and IPC

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1.5	C 07 D 207/34	C 07 D 401/12	C 07 D 233/90
A 61 K 31/40	A 61 K 31/415		

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.C1.5

C 07 D 207/00 C 07 D 233/00 C 07 D 401/00

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category °

Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²

Relevant to Claim No.¹³

A

Chemical Abstracts, vol. 98, 1983, (Columbus, Ohio, US), A.A. KHORLIN et al.: "DNA base pair sequence specific ligands. VIII. Synthesis of AT-specific ligands built of two netropsin-like molecules linked symmetrically by residues of different aliphatic dicarboxylic acids", see page 686, abstract no. 72699f, & BIOORG. KHIM. 1982, 8(10), 1358-64, see entire abstract

1-31

A

Chemical Abstracts, vol. 93, 1980, (Columbus, Ohio, US), A.A. KHORLIN et al.: "A new type of AT-specific ligand constructed of two netroprosin-like molecules", see page 224, abstract no. ~199447z, & FEBS LETT. 1980, 118(2), 311-14, see entire abstract

1-31

° Special categories of cited documents : 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*O document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

27-03-1992

Date of Mailing of this International Search Report

27 APR 1992

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

MISS I. TAZELAAR

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	
X	US,A,4665184 (P.B. DERVAN et al.) 12 May 1987, see RN 116845-82-4: Heptanediamide, N,N'-bis[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- ---	1-31
X	J. Med. Chem., vol. 32, 1989, American Chemical Society, J.L. LOWN et al.: "Novel linked antiviral and antitumor agents related to netropsin and distamycin: Synthesis and biological evaluation", pages 2368-2375, see entire publication ---	1-31
X	US,A,4912199 (LOWN et al.) 27 March 1990, see entire document (cited in the application) ---	1-31
A	WO,A,9110649 (CARLO ERBA) 25 July 1991, see entire document ---	1-31
A	J. Med. Chem., vol. 31, no. 2, February 1988, American Chemical Society, K. KROWICKI et al.: "Novel DNA groove binding alkylators: Design, synthesis, and biological evaluation", pages 341-345, see entire publication (cited in the application) ---	1-31
A	GB,A,2178037 (CARLO ERBA) 4 February 1987, see entire document ---	1-31
A	GB,A,2178036 (CARLO ERBA) 4 February 1987, see entire document ---	1-31
P,X	J. Org. Chem., vol. 56, no. 2, 1991, American Chemical Society, K.W. RAO et al.: "Sequence-selective DNA binding by linked Bis-N-methylpyrrole dipeptides: An analysis by MPE footprinting and force field calculations", pages 786-797, see entire publication ---	1-31
X	Chemical Abstracts, vol. 116, 1992, (Columbus, Ohio, US), K.E. RAO et al.: "Novel linked antiviral and antitumor agents related to netropsin - 2: synthesis and biological evaluation", see page 844, abstract no. 42027h, & ACTUAL. CHIM. THER. 1991, 18 (RENCONTRES INT. CHIM. THER., 26TH, 1990), 21-42, see entire abstract -----	1-31

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers
Authority, namely: because they relate to subject matter not required to be searched by this
Remark: Although claim 14 is directed to a method of treatment of (diagnostic method practised on) the human /animal body the search has been carried out and based on the alleged effects of the compound/composition."
2. ☒ Claim numbers
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

see next page
3. ☐ Claim numbers
the second and third sentences of PCT Rule 6.4(a). because they are dependent claims and are not drafted in accordance with

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Lack of conciseness

The definition of the following substituent(s) is too general and/or encompasses too broad a range of totally different chemical groups, only partly supported by examples given in the descriptive part of the application:

A: "a moiety bearing a positive charge and of a size which does not inhibit binding of said compound to nucleic acid sequences associated with the cellular action of retroviruses".

x,y,z

Het: a five membered heterocyclic ring

The vast number of theoretically conceivable compounds resulting from the combination of all claimed substituents of above list precludes a comprehensive search. Guided by the spirit of the application and the inventive concept as disclosed in the descriptive part of the present application the search has been limited to the following case(s):

A: amidines, guanidines, ammonium salts

x,y,z not equal 0

Het: pyrrole, imidazole

Obscurity:

Formula I is unclear: (CONH)_x and attachment of amido/carboxamido groups to Het

Searched: 4-carboxamido-Het-2-carboxamides(4-CO-NH-Het-2-CO-NH-Het)

(Cf. Arts. 6, 15 and Rule 33 PCT, guidelines Exam. Part B, Chapt III, 3.6, 3.7)

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

CA 9200051
SA 56216

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 21/04/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4665184	12-05-87	US-A- 4942227	17-07-90
US-A- 4912199	27-03-90	None	
WO-A- 9110649	25-07-91	AU-A- 7059991	05-08-91
		CN-A- 1053230	24-07-91
		EP-A- 0462258	27-12-91
GB-A- 2178037	04-02-87	AT-B- 386822	25-10-88
		AU-B- 584723	01-06-89
		AU-A- 6020386	22-01-87
		BE-A- 905109	15-01-87
		CA-A- 1247627	27-12-88
		CH-A- 671958	13-10-89
		DE-A- 3623853	29-01-87
		FR-A- 2585019	23-01-87
		JP-A- 62030755	09-02-87
		NL-A- 8601838	16-02-87
		SE-A- 8603099	17-01-87
		SU-A- 1535378	07-01-90
		SU-A- 1538893	23-01-90
		US-A- 4738980	19-04-88
GB-A- 2178036	04-02-87	AT-B- 387013	25-11-88
		AU-B- 587841	31-08-89
		AU-A- 6020286	22-01-87
		BE-A- 905110	15-01-87
		CH-A- 674206	15-05-90
		DE-A- 3623880	29-01-87
		FR-A- 2585018	23-01-87
		JP-A- 62077362	09-04-87
		NL-A- 8601837	16-02-87
		SE-A- 8603098	17-01-87
		SU-A- 1544185	15-02-90
		SU-A- 1609445	23-11-90
		US-A- 4766142	23-08-88

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)